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About 90 lyophilised protein drug products are currently marketed in the United States or Europe. 
These biopharmaceuticals cover monoclonal antibodies, hormones, enzymes, vaccines, and fusion 
proteins [1, 2]. Proteins are commonly freeze-dried to overcome or reduce instabilities that may occur 
in liquid state. Stabilisers and excipients are added to form an amorphous matrix, in which the protein 
molecules are embedded and show enhanced stability [3]. Sucrose is the classically used amorphous 
matrix former. Two theories can explain its stabilising mechanism: the water replacement theory and 
the vitrification concept. The water replacement theory relies upon hydrogen bonding between the 
sugar and the protein molecules, thus replacing the water molecules at the protein surface. Thereby, 
the sugar molecules stabilise the native conformation of the protein [4]. According to the vitrification 
concept, protein mobility is substantially reduced in the glassy matrix, and reaction rates between 
protein molecules and between a protein molecule and, for example, water, oxygen, or other reactive 
species are decreased [5, 6]. In order to obtain a pharmaceutically acceptable parenteral product, 
excipients are required to provide protein stability but also isotonicity, physiologically compatible pH, 
and elegant appearance. In the following we discuss the typically used excipients as well as the 
potential of new excipients in freeze-drying of proteins. Some excipients fulfil multiple functions; for 
example, histidine acts as protein stabiliser, reducing aggregation and at the same time acting as 
buffer, and surfactants can stabilise the protein against freezing stress but also may accelerate 
reconstitution. In the following, the excipients are structured in a matrix by chemical nature and 
functionality to improve understanding, which is shown in Figure 1-1. 
 





2. Sugars and polyols 
2.1 The commonly used: sucrose, trehalose, and mannitol 
The two disaccharides sucrose and trehalose are most commonly used in lyophilisation as protein 
stabilisers. They are approved for various parenteral routes. The small and flexible sugar molecules are 
able to cover the protein surface, forming hydrogen bonds with the protein molecules. Both form 
amorphous matrices, which are key for protein stabilisation. Thus, they act as both cryo- and 
lyoprotectant. 
Sucrose is the most frequently used sugar in the freeze drying of biopharmaceuticals. Besides the cryo- 
and lyoprotective effects of sucrose, a key feature is that it is a non-reducing disaccharide. A Tg’ of -32°C 
and a Tg of 74°C make sucrose favourable for both the lyophilisation process and the storage stability 
[7]. Solid contents of up to 10% (w/w) are suitable to form elegant cakes and to achieve isotonic 
products after reconstitution [8]. Nevertheless, the glycosidic bond of sucrose may be cleaved, forming 
the reducing monosaccharides glucose and fructose, which results in Maillard reactions with protein 
or amino group-carrying excipients [9]. Thus, even more stable stabilisers are pursued. Furthermore, 
there is interest in sugar matrices with a higher Tg’ or Tc to achieve faster primary drying processes 
[10]. Recently, the pharmaceutical grade of sucrose was found to contain some nanoparticulate 
impurities [11]. 
Trehalose has emerged as an alternative to sucrose in lyophilisation after the approval of the first 
lyophilisate stabilised with trehalose Herceptin®, which contains trastuzumab. The glycosidic bond of 
this non-reducing disaccharide is more stable than that of sucrose [9]. Additionally, trehalose shows 
higher Tg’ and Tg values than sucrose, with -28°C and 119°C, respectively [7]. Trehalose can crystallise 
as dihydrate during freezing, which can negatively impact protein stability. Crystallisation can be 
inhibited by a combination with sucrose, for example [12]. Furthermore, trehalose dihydrate formation 
occurs mainly during annealing, but upon drying, the dihydrate converts into the amorphous 
anhydrate [13].  
The sugar alcohol mannitol is used on regular basis as bulking excipient for protein lyophilisates. 
Amorphous mannitol can help to stabilise proteins, such as LDH, β-galactosidase, and l-asparaginase, 
but has low Tg’ values of −32°C and −25°C and a very low Tg of 12.6°C with a high tendency to crystallise 
[14, 15]. Upon crystallisation mannitol loses its ability to stabilise proteins. Mannitol forms different 
polymorphs as well as a hemihydrate depending on the crystallisation temperature, rate, and the 
annealing step during the lyophilisation process [16]. The crystallisation leads to a scaffold, which not 
only provides pharmaceutically elegant cake appearance but also enables process temperatures during 




primary drying above the Tg’ or the collapse temperature Tc of the amorphous matrix. Exemplarily, at 
a mannitol to sucrose ratio of 4:1, primary drying can be run at −10°C product temperature [17]. The 
amorphous sucrose matrix at this ratio stabilises proteins sufficiently [18]. 
 
2.2 Other small saccharides and polyols 
Sucrose is chosen widely for freeze drying formulations because of its protein stabilising efficiency. 
However, amorphous sucrose-based formulations show often relatively low Tg values and can show 
stability problems when stored at higher temperatures or elevated humidities [19]. Various 
saccharides are under investigation because of their different physical properties and protein-
stabilising effects [20]. 
Maltose showed the ability to maintain BSA and ovalbumin conformation during freeze-drying, 
whereas maltooligosaccharides had decreased stabilising effects with increasing saccharide units [21].  
Screening different disaccharides regarding their stabilising effect of freeze dried β-galactosidase 
resulted in about 60% remaining activity after 90 days at 45°C for the following sugars: sucrose, 
trehalose, cellobiose (glucose and glucose), isomaltulose (glucose and fructose), and melibiose 
(galactose and glucose). However, cellobiose, isomaltulose, and melibiose all belong to the group of 
reducing sugars and may therefore induce the Maillard reaction [7]. 
Owing to their higher molecular weight, trisaccharides require more solid content to reach isotonicity 
in freeze-drying formulations. This, on the one hand, may provide more amorphous matrix mass in 
which protein molecules are embedded and could be considered beneficial especially at high protein 
concentration to reduce interactions. On the other hand, a higher total solid content may slow down 
drying and delay reconstitution. Furthermore, large saccharides can provide high Tg values [21], but 
are reported to be less effective in protein stabilisation due to steric hinderance with increasing size 
[22]. Melezitose, a non-reducing trisaccharide based on two glucose and one fructose unit and 
produced by plant eating insects, which shows a high Tg of 160°C, was evaluated for lyophilisation of 
blood and plasma proteins. The stabilising effect for factor VIII was better than trehalose during 
processing and after storage at 40°C for 4 weeks. Furthermore, melezitose provided good stability of 
factor IX, rFVIII, pFIX, and rHES-G-CSF lyophilisates over 6 months [23-25]. 
Raffinose is composed of galactose, glucose, and fructose, but it is a nonreducing sugar owing to its 
chemical stability. It forms amorphous lyophilisates with a Tg’ of −26°C and a Tg of 109°C. Annealing at 
−10°C results in the crystalline raffinose pentahydrate form, which was dehydrated during primary 





the final product containing 5% to 14% raffinose was amorphous [7, 26]. The stabilising potential of 
raffinose via water replacement appears to be inferior to sucrose. Whereas 100% raffinose resulted in 
a markedly higher Tg of 37°C at approximately 5% residual moisture than sucrose and raffinose/ 
sucrose mixtures, the remaining LDH activity was higher with higher sucrose content upon storage at 
44°C for 45 days [27].  
While mannitol is used as a crystalline bulking agent, other polyols, which form an amorphous phase 
could act as cryo- and lyoprotectors. Furthermore, small polyols like glycerol and sorbitol can act as 
plasticisers, excellent hydrogen-bond formers, and void fillers in glasses [28-31]. 
The plasticising effect of glycerol leads to a Tg decrease and a molecular mobility increase of a sugar 
matrix [28, 32]. Adding a small amount of glycerol to a trehalose formulation decreased the protective 
effect of trehalose to lysozyme during primary drying owing to the plasticiser behaviour. In secondary 
drying, glycerol showed an antiplasticising effect by forming strong hydrogen bonds with trehalose, 
thereby suppressing fast local dynamics of trehalose [33]. Interestingly, adding small amounts of the 
plasticiser sorbitol to a sucrose formulation for an IgG1 resulted in a decrease in subvisible particle 
levels after lyophilisation as well as after subsequent storage at 40°C for 4 weeks, even at a relatively 
high sucrose to protein ratio of 10:1 [34]. 
The sugar alcohols maltitol, lactitol, and maltotriitol were able to form amorphous glasses during 
freeze-drying and prevented activity loss of LDH upon storage even at 50°C. They also protected bovine 
serum albumin from lyophilisation-induced secondary structure perturbation. In contrast, xylitol, a 
pentitol, and the hexitols sorbitol and mannitol collapsed or resulted in crystalline solids [35]. 
The sweetening agent and tabletting excipient isomalt consists of two stereoisomers, 6-O-α-d-
glucopyranosyl-d-sorbitol and 1-O-α-d-glucopranosyl-d-mannitoldihydrate. Isomalt forms amorphous 
lyophilisates, which did not crystallise even at up to 16% residual moisture. Stereoisomer mixtures at 
four different ratios could not prevent a loss of LDH activity during freeze-drying, but preserved the 
enzymatic activity better than sucrose during long term stability testing [36, 37]. Overall, the polyols 
could be options for protein stabilisation, potentially in mixture with sucrose. 
Meso-erythritol was identified as potential bulking agent for lyophilisation due to its high crystallisation 
propensity [38], but it has not been tested with biopharmaceuticals. 
 




2.3 Oligo- and polysaccharides 
Dextrans are oligo-glucosides, which stay amorphous during lyophilisation [39, 40]. Pure 70 kDa and 
6 kDa dextran show in solution Tg’ values of −11°C and −14°C and Tg values of 167°C and 144°C, 
respectively. Adding 70 kDa dextran to trehalose at a 1:1 ratio led to an increase of Tg’ from −28°C to 
−20°C and of Tg from 88°C to 110°C. However, pure 70 kDa dextran and dextran/trehalose 
combinations did not improve the stability of insulin, LDH, β-galactosidase, and HBsAg upon storage at 
60°C (<10% r.h.) for 4 weeks as compared to trehalose [41]. Along with other polymers, dextrans can 
cause liquid-liquid phase separation during freeze concentration when used as cryoprotectant [42, 43]. 
The 4 kDa fructane inulin also results in higher Tg’ and Tg values of −17°C and 154°C, as compared to 
−28°C and 121°C of trehalose, respectively. However, inulin did not improve storage stability of 
proteins at 60°C for 4 weeks as compared to trehalose, although it performed better than 70 kDA 
dextran [41]. 
Another polyglucoside, which can be used as amorphous Tg’ and Tg modifier, is maltodextrin, which is 
obtained by partial hydrolysis of starch. Five-percent maltodextrin with a dextrose equivalent (DE) of 
5 or 8 showed a Tg’ of -10°C and enables faster drying cycles [18]. Formulations containing maltodextrin 
DE 5 or 8 and Polysorbate 80 or polyethyleneglycol PEG ensured stability of two Clostridium difficile 
toxins at ambient temperature [18]. In general, the dextrans, inulin, and maltodextrin have chemically 
reactive end-groups and should therefore be used with care in a protein formulation. 
Whereas hydroxyethyl cellulose (HEC) 90 kDa, known as a gelling and thickening agent, provided better 
protection of LDH against freeze-thaw stress than sucrose, less activity was found after freeze-drying 
than with sucrose. The HEC lyophilisates had a high Tg of 160°C, but reconstitution took 40 min for 1% 
HEC [44]. 
Hydroxyethyl starch (HES) shows similar benefits as dextran on the physical properties of lyophilised 
proteins (see 3.2.3). Whereas interleukin-11 (rhIL-11) lyophilisates with 2.5% 200 kDa HES as sole 
excipient showed high Tg, indicating potentially high storage stability, HES failed to inhibit lyophilisation 
and storage-induced unfolding of rhIL-11. The combination of 2.5% HES with 2.5% or 5% sucrose or 
trehalose formulation of rhIL-11 resulted in good storage stability through water replacement by the 
sugar molecules and the increased Tg values arising from HES [45]. The stability of HESylated interferon 
α-2b was superior to PEGylated, indicating a beneficial effect of HES also in conjugated form [46]. 
Cyclodextrins (CDs) are cyclic, nonreducing oligoglucosides and can be differentiated into three main 
classes, α-, β-, and γ-CDs, which are composed of six, seven, and eight glucose molecules, respectively. 





stabilise poorly water-soluble compounds. Owing to systemic toxicity concerns and to increase water 
solubility, CDs are functionalised [47, 48] and hydroxypropyl- and sulfobutyl-CDs are approved for 
parenteral products [49, 50].  
With their hydrophobic pocket, CDs can interact with lipophilic amino acid side chains of proteins, 
ultimately reducing hydrophobic interactions. Thus, CD-derivates can reduce protein aggregation in 
liquid and could stabilise proteins during cooling, freezing of solutions and upon rehydration of 
lyophilisates [51].  
CD derivates can increase Tg values; for example, freeze-dried β-CD with interleukin-2 (IL-2) had an 
increased Tg up to 108°C with 2.5%–3.5% RM, which might enhance protein stability during storage 
[52, 53]. Furthermore, HP-β-CD provides a high collapse temperature Tc of −9°C [54, 55]. 
At higher concentrations, HP-ß-CD stabilises proteins via water-replacement and vitrification [56]. 
Addition of HP-β-CD to trehalose reduced the aggregation of an IgG with an optimal mass ratio of 
trehalose to HP-β-CD of approximately 3.3 to 1 [57]. Both pure trehalose and pure HP-β-CD kept the 
IgG aggregation level low in formulations containing 80% carbohydrate and 20% IgG [58]. HP-α-CD, 
HP-β-CD, PM-β-CD, and HP-γ-CD preserved LDH activity during freeze-drying with more than 80% 
preserved, compared to trehalose with 70% [56]. 
Low HP-β-CD concentrations of about 0.1% provide a surfactant-like prevention of protein aggregation 
at interfaces. HP-β-CD may thus be an alternative to polysorbate or poloxamer in protein drug 
products, especially in case of a low specific surface area of the product [59]. 
 
3. Amino acids 
Amino acids are commonly used in protein liquid formulations as buffer systems, to stabilise the native 
protein structure, to enhance protein solubility, or to reduce viscosity at high concentration [60-62].  
With respect to protein lyophilisates it is suggested that charged amino acids may be good void fillers 
of amorphous sucrose matrices. In this respect positively charged amino acids had an advantageous 
stabilising effect on human serum albumin (rHSA), potentially related to their larger molar volume, as 
compared to negatively charged amino acids [32]. Amino acids are known for their low Tg’ values, for 
example −62°C for glycine [63] or −42°C for l-arginine and −47°C for l-arginine∙HCl [64], which can be 
critical for the lyophilisation process [65, 66]. Nevertheless, freeze-dried amino acids resulted often in 
high Tg values, for example about 90°C for l-arginine with citrate or about 100°C for l-histidine citrate, 
both around pH 6 [67]. Furthermore, amino acids like glycine and phenylalanine crystallise during 




freeze drying and can therefore act as bulking agents [66, 68-70]. A glycine to raffinose or trehalose 
ratio of at least approximately 1.2 to 1.5 is required to render crystalline glycine, which enables 
manufacturing of elegant lyophilisates even at a primary drying temperature 10°C above Tg’. The 
combination of sugar and bulking agent prevented loss of LDH activity during freeze drying [71]. At low 
glycine to sugar ratios, glycine can be present in the amorphous state and is able to improve protein 
stability. Being a low-molecular-weight plasticiser, glycine can increase solid-state stability of mAbs 
despite lowering Tg [72]. Amorphous glycine was found to increase the activity of freeze-dried factor V 
and factor VIII formulations [73]. 
Arginine has weak affinity to the protein surface, which indicates that the stabilisation effect of 
arginine is not due to preferential exclusion. It is able to form hydrogen bonds with protein molecules 
upon lyophilisation, and in addition ion dipole interactions are possible owing to its positive charge 
[62, 74, 75]. The mechanisms on the molecular level are still discussed, but protein-protein interactions 
and aggregation are prevented mainly because of weak binding of arginine to the proteins [62].  
In mixtures with a hydroxy di- or tricarboxylic acids, arginine and histidine show bell-shaped changes 
in the Tg’ profiles, with low Tg’ values for low and high carboxylic acid concentrations. For example, 
l-arginine and pure citric acid have Tg’ values of -44°C and -55°C, respectively, but in combination at a 
1:1 ratio for pH adjustment the Tg’ is increased up to a maximum of around -25°C [67]. The Tg’ of 
histidine increases from -47°C at pH 4.0 to -31°C upon pH adjustment to 7.7 with hydrochloric acid. 
Addition of sucrose to the histidine-containing formulation leads to an additional increase in Tg’ [76]. 
Stärtzel et al. freeze dried 50 mg/ml mAb in ratios 16:64 and 64:16 arginine to sucrose, testing chloride, 
citrate, phosphate, and succinate as counter ions. Major cake defects were observed with chloride, 
whereas all other formulations rendered only minor defects. The Tg values were between 58°C and 
86°C [77]. Addition of arginine hydrochloride to sugar-based BSA lyophilisates reduced protein 
aggregation during manufacturing and upon storage [78]. Arginine exhibits a stabilising effect also if 
the product is collapsed, as shown for the aggregation propensity of an IgG1 in arginine phosphate 
pH 7.3 [79]. Albumin used to stabilise recombinant factor VIII during lyophilisation can be replaced by 
l-arginine, l-glutamic acid, and l-isoleucine. The mixture of 36 mM arginine, 57 mM glutamic acid, and 
7 mM isoleucine was as effective as albumin [80]. 
Adding histidine to sucrose formulations resulted in decreased aggregation levels of an IgG but a 
perturbed secondary structure. Solid-state hydrogen-deuterium exchange and Fourier-transform 
infrared spectroscopy did not predict protection through histidine, and ionic interactions or 
suppressed dynamics might be the reason for the perturbation [81]. Freeze drying LDH in pure histidine 





concentration, was found optimal at pH 6, higher than citrate and phosphate buffers [82]. Both for 
fibroblast growth factor 21 and catalase, testing different formulations demonstrated stabilising 
effects of various amino acids. Regarding aggregation and bioactivity of fibroblast growth factor 21, a 
formulation containing 2% mannitol, 2% trehalose, 0.05% glycine, and 0.1% Poloxamer 188 preserved 
the protein best [83]. Alanine, glycine, serine, arginine, histidine, lysine, 4-hydroxy proline, and 
threonine showed a stabilising effect on catalase activity, while the stabilising effect other amino acids 
was weaker and concentration dependent [84]. 
Phenylalanine, isoleucine, and leucine crystallise during lyophilisation and can therefore be used as 
bulking agents. Starting at low ratios of 2.5:47.5 amino acid to sucrose, the bulking efficiency improved, 
and a pharmaceutical elegant cake was obtained at a ratio of 5:45. Neither 2 mg/ml nor 50 mg/ml mAb 
suppressed crystallization of leucine and isoleucine [68]. Thus, compared to mannitol and glycine, less 
amino acid is required to form a crystalline scaffold. Consequently, more sugar can be used in the 
formulation to generate a higher stabiliser to protein ratio. 
l-Glutathione can be used as antioxidant to increase the storage stability of proteins, for example, 
factor VIII [85]. An antioxidative effect can also be achieved with methionine already at rather low 
concentrations [2, 86, 87]. Exemplarily, some commercial hormone (Pergoveris®, Gonal-f®) and 
coagulation factor (NovoEight®, NovoSeven®) products contain methionine as antioxidant. 
Glycylglycine is used as buffering agent for stabilisation of freeze-dried factor VIIa (NovoSeven®), which 
showed, along with glycine, stabilising effects during freeze-thaw experiments [88], but a specific 
stabilising effect in lyophilisation has not been reported yet [89, 90]. 
 
4. Polymers 
Dry amorphous polymer matrices may stabilise proteins similarly to sugar matrices (see also 3.2.3). 
They were thought to even be superior owing to their high Tg values, as already described above in 
sugar polymers (see 3.2.3). However, they are less capable of water replacement, and therefore 
combinations with small-molecule excipients are typically required to achieve adequate protein 
stability. Polymers may also prevent proteins from aggregating owing to their surface active properties, 
through sterical hindrance of protein-protein interactions as well as via increased viscosity, reducing 
protein structural movement [91, 92].  
However, polymers may trigger phase separation, which can have a detrimental effect on protein 
stability [93]. 




Adding up to 20% PEG decreased the Tg’ of 10% sucrose to −48°C. Upon annealing at −25°C, PEG 
crystallised [94]. Higher PEG concentrations show the risk of phase separation, and the protein may 
concentrate in one phase, increasing the risk of aggregation [93, 95]. Initially amorphous PEG is prone 
to crystallise during primary drying, which could induce protein aggregation. Interestingly, this 
crystallisation could be inhibited by higher sucrose amounts [96]. A collapsed lyophilisate containing 
LDH with sucrose or trehalose to PEG at a ratio of 3:2 showed the same monomer content and 
subvisible particle level as a noncollapsed cake [79]. On long-term stability at 40°C for 26 weeks, the 
collapsed cakes remained the same or showed higher monomer content and less subvisible particle 
level as noncollapsed cake [97]. Interestingly, trehalose glycopolymers (2–50 kDa) resulted in higher 
remaining activity than polyethylene glycol after freeze-drying and thermal stress [98]. 
Adding copovidone, a copolymer of 1-vinl-2-pyrrolidone (60%) and vinyl acetate (40%) to a lysozyme 
formulation without further excipients maintained biological activity and conformation integrity 
during freeze-drying and subsequent storage [99]. Similar results were found for PVA on the stability 
of β-galactosidase [100].  
 
5. Surfactants 
During freezing, proteins are exposed to the ice-water interface, which can contribute to freezing-
induced protein denaturation and aggregation. By addition of surfactants, proteins can be protected 
from both freezing- and surface-induced denaturation [101]. Surfactants may also potentially foster 
protein refolding, reducing aggregation in the reconstitution step [31, 102]. The most commonly used 
surfactants in commercial lyophilized protein products are polysorbate 20 and 80. Exemplarily, 
polysorbate 80 is used for Benlysta®, Inflectra®/Flixabi®, and Empliciti®, and polysorbate 20 for Xolair® 
and Herceptin® products [2]. Polysorbate is prone to degradation, such as oxidation, autoxidation, and 
hydrolysis, which are influenced by various factors including pH, temperature, and oxygen level. 
Degradation is more pronounced in liquid than in lyophilised state [103-105].  
Poloxamer 188 is a water-soluble surface-active polyoxyethylene-polyoxypropylene triblock 
copolymer. It can also compete with the protein for interfaces, preventing adsorption-induced 
conformational changes and aggregation [75], and is exemplarily used for Gazyvaro®. 
Trehalolipids are reported to have surfactant-like abilities [106, 107]. They are of interest as stabilisers 
for lyophilisation processes owing to their glass-forming ability [108]. Sugar-based surfactants can be 
used as alternative to polysorbate eliminating the instability-prone polyoxyethylene moiety [107]. 





in maintaining LDH activity to pure trehalose. The Tg of both sugar-based lipid formulations was as 
approximately  85°C [109]. Trehalolipids did prevent aggregation of IL-11, similarly to polysorbate 80, 
during freeze-drying and upon short term storage at 50°C for 1 week [107]. 
 
 
Figure 1-2: Structures 6-O-octanoyl trehalose, and 6-O-lauroyl raffinose. 
 
6. Buffer 
Protein injectables typically require pH adjustment and stabilisation with buffers. Exemplary well-
known buffer systems are histidine (see amino acids in buffer systems in section 3) and phosphate, 
succinate, or citrate [110]. Buffers used in commercially available freeze-dried antibody drugs are 
shown in Table 1-1. Some buffer species can selectively crystallise, causing pH changes. Disodium 
phosphate has lower solubility than monosodium phosphate, potentially leading to earlier 
crystallisation upon concentration during freezing and causing a pH shift of up to 3 pH units [111-114]. 
This effect is less pronounced for potassium phosphate buffers [115]. Furthermore, succinate buffer is 
prone to crystallisation and therefore to pH shifts, which can be inhibited by amorphous sucrose, 
trehalose, glycine, and mannitol [116]. Higher antibody concentrations show self-buffering 
characteristics as well as inhibition of the beforementioned pH shifts. At 50 mg/ml, antibody can act 
similar to 6 mM citrate or 14 mM histidine buffer [117]. 
Buffers not only affect protein stability via the pH but also by potential direct interaction or changing 
the mobility in the glassy matrix. During freezing protein stability can be increased by phosphate and 
citrate, which do not act as strong hydrogen-bonds formers, in formulations with stabilisers such as 
sucrose, which is preferentially excluded in solution [118]. It is often proposed to use low buffer salt 































protein stability. Since buffer salts as well as sodium chloride added as tonicity agent or resulting from 
pH-adjustment with acid or base decrease the Tg’ of the formulations, the collapse tendency is 
increased [119]. However, the dibasic phosphate ion HPO42- is also able to increase the Tg of sugar 
formulations at higher pH values. While trehalose showed a Tg of 94°C at different pH values, the Tg 
was increased by phosphate to 119°C at pH 7.5 [120]. Through self-aggregation of HPO42- ions, a 
hydrogen network with trehalose is built, whereas the monobasic phosphate ion H2PO4- does not form 
such network and decreases the Tg, acting as a plasticiser [121]. 
Carboxylic acids and their sodium salts, such as sodium citrate, protected the secondary structure of 
BSA and IgG better with increasing concentrations. This suggested stabilisation through direct 
interactions by substitution of water molecules [122]. Furthermore, addition of sodium citrate to a 
sucrose formulation led to an increase in Tg from 70°C up to 150°C at a sodium citrate to sucrose ratio 
of 3:1 [123]. The stability of highly concentrated mAb (40 – 160 mg/ml) freeze-dried with sucrose or 
trehalose was substantially improved in the presence of succinate buffer as compared to a buffer-free 
system [124]. Furthermore, sodium tetraborate increased Tg’ and Tg of BSA / sugar formulations [21]. 
The buffering agent dimethyl-succinate was found to stabilise lignin peroxidase as effectively as 






Table 1-1: Commonly used buffers for freeze-dried antibody drugs commercially available, adapted from Gervasi 
et al. [2]. 
Buffer 
International Nonproprietary Name 
(INN) 
Trade Name 
Citrate belimumab Benlysta® 
 blinatumomab Blincyto® 
 brentuximab vedotin Adcetris® 
 etoluzumab Empliciti® 
Histidine canakinumab Cosentyx® 
 omalizumab Xolair® 
 pembrolizumab Keytruda® 
 secukinumab Cosentyx® 
 siltuximab Sylvant® 
 
trastuzumab Herceptin®; Herzuma®; Kanjinti®; 
Ontruzant® 
 vedolizumab Entyvio® 
Lysine blinatumomab Blicyto® 
Phosphate basiliximab Simulect® 
 
infliximab Flixabi®; Inflectra®; Remicade®; 
Remsima® 
 gemtuzumab ozogamicin Mylotarg® 
 mepolizumab Nucala® 
Succinate trastuzumab emtansine Kadcyla® 




HSA, also in the recombinant form, can prevent protein adsorption to surfaces and act as water 
replacement molecules, maintaining protein activity [111, 126]. HSA is used mostly for solubilising and 
protecting low-dosed and hydrophobic proteins such as cytokines, coagulation factors, or botulinum 
toxin [87, 126]. The utilisation of HSA in parenteral drug products comes along with immunogenicity 
concerns because of the proteinaceous nature of the excipient and the potential formation of mixed 




aggregates. Additionally, HSA impacts protein analytics. Replacement of HSA in lyophilised products 
can be achieved by combining surfactants with an amino acid like glycine, arginine, or histidine [126-
128]. 
Other protein excipients that are not approved for use in human parenteral drug products are 
intrinsically disorders proteins (IDPs). IDPs can act as cryoprotectants, and an IDP to LDH ratio of 10:1 
resulted in similar activity levels after freeze-drying as BSA [129]. Comparing different proteinaceous 
additives, only the weakly acidic proteins BSA and ovalbumin stabilised LDH as well as other enzymes; 
however, the effectiveness was limited as compared to sugars [130]. 
 
7.2 Alcohols 
In the past, cosolvent systems have been used to improve dissolution characteristics and drying times 
of lyophilised products [131, 132]. The addition of 0.5% and more TBA to a albiglutide (GLP-1 agonist) 
formulation resulted in a reduction of reconstitution time [133]. 
 
7.3 Preservatives 
Multidose protein formulations require preservation. Intron A® (Interferon α-2b) is a commercially 
available multidose product that contains benzyl alcohol as preservative in the solid. In other cases, 
benzyl alcohol is part of the reconstitution medium, for example, in Novarel®, Pregnyl®, and Profasi®, 
all three containing human chorionic gonadotropin, and Nutropic®, containing human growth 
hormone [89]. Benzyl alcohol can substantially decrease the protein aggregation temperature and can 
increase protein aggregation in liquid [134]. Reconstitution of rhIL-1ra with 0.9% benzyl alcohol in 
water resulted in a higher level of aggregation than reconstitution with water for injection. 
Nevertheless, once in a liquid state, benzyl alcohol did not accelerate aggregation of rhIL-1ra at room 
temperature [135]. CroFab® (Crotalidae polyvalent immune Fab) contains thiomersal as preservative 
in the lyophilisate [89]. 
 
8. Expert opinion 
Excipients are crucial for providing the chemical and physical stability of protein drugs in lyophilisates. 
The excipients serve different functions and sometimes combine several roles. A substantial list of 





old approved sucrose, or potentially trehalose, combine it with surfactant and buffer selected from a 
small portfolio, if necessary, complement this with crystalline-bulking agent, typically mannitol, and 
specific stabilisers, which usually function both in the liquid and the dry state. 
Sucrose is the gold standard for providing an amorphous matrix and water replacement. Only a few 
sugars and amino acids are good alternatives, specifically trehalose, HP-β-CD, or arginine. Bulking 
agents provide pharmaceutically elegant cakes and potentially enable faster primary drying. Mannitol 
plays the leading role, with glycine, phenylalanine, leucine, and isoleucine as potential other options. 
Cake elegance also comes with high protein drug content and increased total solid content. Overall, 
the need for new bulking agents is low, except for bulking agents that can be used at lower 
concentration in order to keep the sugar stabiliser content high considering isotonicity. In this context 
reconstitution time, which can become very long at high protein drug concentration, may need to be 
considered upon excipient selection, as total solid content and cake structure affect the water 
penetration into the lyophilized cake. 
Some excipients under evaluation do not lead to improved protein stability. Instead they provide 
higher Tg’ for more robust primary drying; higher Tg is not necessarily correlated with stability and 
lyophilisate elegance. A few larger saccharides and polysaccharides like melezitose, raffinose, inulin, 
dextran, maltodextrin, HEC, and HES serve this function. 
The most suitable pH is often identified already in a liquid screening. The buffer should be selected 
considering its crystallisation tendency and potential pH shift upon freezing, which can harm the 
protein and may lead to a discrepancy between the pH value adjusted in the liquid state and the 
theoretical pH in the solid state. 
In most cases, surfactant is added, again selected from a small group consisting of polysorbate 20, 
polysorbate 80, and poloxamer 188, although many more surface-active molecules would be available. 
Addition of an antioxidant is advisable in the case of highly oxidation-sensitive protein molecules. The 
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Objectives of the Thesis 
Lyophilisation is a commonly used method to prolong the shelf life of biopharmaceutics [1]. 
Understanding the process and its parameters during the three phases freezing, primary drying, and 
secondary drying, are key. The freezing step gained special interest amongst researchers as it impacts 
the entire process and the final product. This first step affects intra- and inter-vial uniformity [2], 
primary and secondary drying rate and product temperature [3], physical state of the sample [4], 
residual moisture [5], reconstitution time [6] and also protein stability [5, 7]. 
During freezing, ice crystallises leading to an upconcentration of solutes in the unfrozen aqueous phase 
forming the freeze concentrate (FC) [8]. The question arises what is the exact composition of the FC, 
specifically how much water is unfrozen and how is the protein stability in the FC. On the one hand 
side the FC is extremely viscous leading to an increased colloidal protein stability due to decreased 
mobility and reaction rates [9, 10]. On the other hand side instabilities can be triggered in the FC due 
to several reasons. A potential phase separation rendering a protein-rich phase with a lower stabilising 
excipient to protein ratio can occur [11-13]. Furthermore the concentration of charged solutes is very 
high, corresponding to a high ionic strength which can result in shielding of repulsive charges at the 
protein surface which are important for colloidal stability [14, 15]. In addition, a pH shift due to the 
temperature change and crystallising buffer components can occur altering the protein stability [16-
19]. Independent of the protein environment in the FC phase, the ice-FC interface is prone for protein 
unfolding [20] and the freezing process impacts the ice-FC interface area [21-26]. Dependent on the 
pH, excipients and protein concentrations, proteins can undergo cold denaturation [24]. 
After ice crystallisation is completed at the end of the freezing step [27], the FC formed has an 
immensely high total solid content of around 70% to 80% (w/w) and 20% to 30% unfrozen water [28-
31]. Comprehensive understanding of the FC composition and analysis of the protein stability in the FC 
will help to improve lyophilisation processes. 
Thus, the first aim of this thesis was to establish an easy DSC method to determine the composition of 
the FC. Subsequently, the solid content in different antibody containing formulations was to be 
analysed (Chapter 3). In a next step, a methodology needed to be established to prepare the FC. With 
the FC at hand, the influence of the upconcentrated solutes on protein stability with a focus on protein 





Sucrose is most frequently used gold standard as amorphous matrix former in lyophilisation of 
biopharmaceuticals due to its cryo- and lyoprotective effect [1, 32]. Despite being a non-reducing sugar 
with a moderate Tg’ of -32°C and high Tg of 75°C, which makes sucrose favourable for both the freeze-
drying process and storage stability, long-term storage at elevated temperature may lead to breaking 
of the glycosidic bond, formation of reducing glucose and fructose units ultimately leading to protein 
glycation [32, 33]. 
Next to disaccharides such as sucrose and trehalose some amino acids are used in freeze-drying in 
combination with sugars due to their buffering capacities sugars, specifically histidine [34], their ability 
to form a crystalline bulking matrix, specifically glycine [35, 36], the formation of an amorphous matrix 
with void filling effect e.g. lysine [37], or a specific positive effect on protein self-interaction and 
aggregation as in case of arginine [38]. 
Among the glass forming amino acids, arginine stands out as protein stabiliser due to its ability to 
reduce protein-protein interactions and aggregation in both liquid formulations and lyophilisates, 
depending on protein, further excipients, and concentrations [38-40]. Arginine is a basic amino acid 
resulting in a high pH in aqueous solution above 10 and exhibits a low Tg’ of -42.7°C [38, 41]. Typically, 
the hydrochloride form is used in protein formulation. Its Tg’ of -46°C is well below that of sucrose, but 
the lyophilisates show a high Tg of 74°C. Other counter ions such as citric acid, phosphoric acid, and 
succinic acid result in a substantially increased Tg’ and Tg [41]. 
The second objective of the thesis was on freeze-dried protein formulations without the need for 
sugars based on arginine. At first the effect of different counter ions, citrate, hydrochloride, 
lactobionate, phosphate, and succinate on cake properties and antibody stability was studied in detail 
considering effects of e.g. pH, antibody concentration and sucrose addition (Chapter 5). As the arginine 
lyophilisates show high Tg values also at higher residual moisture and due to the known risk of 
overdrying [42], the influence of the residual moisture content on protein stability in arginine 
lyophilisates was to be studied (Chapter 6). Arginine hydrochloride shows the best protein stabilisation 
amongst the arginine salts. But it comes with low Tg’ and product collapse. Finally, to combine the 
excellent stabilising with good cake properties different approaches, e.g. high protein concentration, 
combination with sucrose as excipient providing a higher Tg’ and mixtures with the crystallizing bulking 
agents mannitol and phenylalanine were evaluated (Chapter 7). 
  





1. Kasper, J.C., G. Winter, and W. Friess, Recent advances and further challenges in lyophilization. 
Eur. J. Pharm. Biopharm., 2013. 85(2): p. 162-9. 
2. Liu, J., et al., A study of the impact of freezing on the lyophilization of a concentrated 
formulation with a high fill depth. Pharm. Dev. Technol., 2005. 10(2): p. 261-72. 
3. Searles, J.A., J.F. Carpenter, and T.W. Randolph, The ice nucleation temperature determines 
the primary drying rate of lyophilization for samples frozen on a temperature‐controlled shelf. 
J. Pharm. Sci., 2001. 90(7): p. 860-871. 
4. Liao, X., R. Krishnamurthy, and R. Suryanarayanan, Influence of processing conditions on the 
physical state of mannitol--implications in freeze-drying. Pharm. Res., 2007. 24(2): p. 370-6. 
5. Passot, S., et al., Effect of controlled ice nucleation on primary drying stage and protein 
recovery in vials cooled in a modified freeze-dryer. J. Biomech. Eng., 2009. 131(7): p. 074511. 
6. Searles, J., Freezing and annealing phenomena in lyophilization, in Freeze Drying/ 
Lyophilization of Pharmaceutical and Biological Products, L. Rey and J.C. May, Editors. 2010, 
Informa Healthcare: London. p. 52-81. 
7. Sarciaux, J.-M., et al., Effects of buffer composition and processing conditions on aggregation 
of bovine IgG during freeze-drying. J. Pharm. Sci., 1999. 88(12): p. 1354-1361. 
8. Hatley, R.H.M. and A. Mant, Determination of the unfrozen water content of maximally freeze-
concentrated carbohydrate solutions. Int. J. Biol. Macromol., 1993. 15(4): p. 227-232. 
9. van de Weert, M. and T.W. Randolph, Physical Instability of Peptides and Proteins, in 
Pharmaceutical Formulation Development of Peptides and Proteins, L. Hovgaard, S. Frokjaer, 
and M. van de Weert, Editors. 2013, CRC Press Taylor & Francis Group: London. 
10. Hagen, S.J., J. Hofrichter, and W.A. Eaton, Protein reaction kinetics in a room-temperature 
glass. Science, 1995. 269(5226): p. 959-62. 
11. Heller, M.C., J.F. Carpenter, and T.W. Randolph, Conformational stability of lyophilized 
PEGylated proteins in a phase-separating system. J. Pharm. Sci., 1999. 88(1): p. 58-64. 
12. Randolph, T.W., Phase separation of excipients during lyophilization: Effects on protein 
stability. J. Pharm. Sci., 1997. 86(11): p. 1198-1203. 
13. Izutsu, K.-I. and S. Kojima, Freeze-Concentration Separates Proteins and Polymer Excipients Into 
Different Amorphous Phases. Pharm. Res., 2000. 17(10): p. 1316-1322. 
14. Lehermayr, C., et al., Assessment of net charge and protein-protein interactions of different 





15. Menzen, T., Temperature-Induced Unfolding, Aggregation, and Interaction ofTherapeutic 
Monoclonal Antibodies. 2014, Ludwig-Maximilians-Universtität München. 
16. Gómez, G., M.J. Pikal, and N. Rodríguez‐Hornedo, Effect of Initial Buffer Composition on pH 
Changes During Far-From-Equilibrium Freezing of Sodium Phosphate Buffer Solutions. Pharm. 
Res., 2001. 18(1): p. 90-97. 
17. Wu, C., et al., Advance Understanding of Buffer Behavior during Lyophilization, in Lyophilized 
Biologics and Vaccines: Modality-Based Approaches, D. Varshney and M. Singh, Editors. 2015, 
Springer New York: New York, NY. p. 25-41. 
18. Kolhe, P., E. Amend, and S.K. Singh, Impact of freezing on pH of buffered solutions and 
consequences for monoclonal antibody aggregation. Biotechnol. Prog., 2010. 26(3): p. 727-33. 
19. Sundaramurthi, P. and R. Suryanarayanan, The effect of crystallizing and non-crystallizing 
cosolutes on succinate buffer crystallization and the consequent pH shift in frozen solutions. 
Pharm. Res., 2011. 28(2): p. 374-85. 
20. Schwegman, J.J., J.F. Carpenter, and S.L. Nail, Evidence of partial unfolding of proteins at the 
ice/freeze-concentrate interface by infrared microscopy. J. Pharm. Sci., 2009. 98(9): p. 3239-
46. 
21. Butler, M.F., Freeze Concentration of Solutes at the Ice/Solution Interface Studied by Optical 
Interferometry. Crystal Growth & Design, 2002. 2(6): p. 541-548. 
22. Pikal, M.J., Freeze-Drying of Proteins, in Formulation and Delivery of Proteins and Peptides. 
1994, American Chemical Society. p. 120-133. 
23. Chang, B.S., B.S. Kendrick, and J.F. Carpenter, Surface-Induced Denaturation of Proteins during 
Freezing and its Inhibition by Surfactants. J. Pharm. Sci., 1996. 85(12): p. 1325-1330. 
24. Bhatnagar, B.S., R.H. Bogner, and M.J. Pikal, Protein Stability During Freezing: Separation of 
Stresses and Mechanisms of Protein Stabilization. Pharm. Dev. Technol., 2007. 12(5): p. 505-
523. 
25. Cao, E., et al., Effect of freezing and thawing rates on denaturation of proteins in aqueous 
solutions. Biotechnol. Bioeng., 2003. 82(6): p. 684-90. 
26. Eckhardt, B.M., J.Q. Oeswein, and T.A. Bewley, Effect of freezing on aggregation of human 
growth hormone. Pharm. Res., 1991. 8(11): p. 1360-4. 
27. Tang, X. and M.J. Pikal, Design of Freeze-Drying Processes for Pharmaceuticals: Practical 
Advice. Pharm. Res., 2004. 21(2): p. 191-200. 
28. Ablett, S., M.J. Izzard, and P.J. Lillford, Differential scanning calorimetric study of frozen sucrose 
and glycerol solutions. J. Chem. Soc., Faraday Trans., 1992. 88(6): p. 789-794. 




29. Miller, D.P., J.J. de Pablo, and H. Corti, Thermophysical Properties of Trehalose and Its 
Concentrated Aqueous Solutions. Pharm. Res., 1997. 14(5): p. 578-590. 
30. Roos, Y. and M. Karel, Amorphous state and delayed ice formation in sucrose solutions. Int. J. 
Food Sci. Tech., 1991. 26(6): p. 553-566. 
31. Roos, Y.H., Frozen state transitions in relation to freeze drying. J. Therm. Anal., 1997. 48(3): p. 
535-544. 
32. Heljo, P., Comparison of disaccharides and polyalcohols as stabilizers in freeze-dried protein 
formulations. 2013, University of Helsinki. 
33. O'Brien, J., Stability of Trehalose, Sucrose and Glucose to Nonenzymatic Browning in Model 
Systems. J. Food Sci., 1996. 61(4): p. 679-682. 
34. Gervasi, V., et al., Parenteral protein formulations: An overview of approved products within 
the European Union. Eur. J. Pharm. Biopharm., 2018. 131: p. 8-24. 
35. Kasraian, K., et al., Characterization of the sucrose/glycine/water system by differential 
scanning calorimetry and freeze-drying microscopy. Pharm. Dev. Technol., 1998. 3(2): p. 233-
9. 
36. Pyne, A. and R. Suryanarayanan, Phase Transitions of Glycine in Frozen Aqueous Solutions and 
During Freeze-Drying. Pharm. Res., 2001. 18(10): p. 1448-1454. 
37. Forney-Stevens, K.M., R.H. Bogner, and M.J. Pikal, Addition of Amino Acids to Further Stabilize 
Lyophilized Sucrose-Based Protein Formulations: I. Screening of 15 Amino Acids in Two Model 
Proteins. J. Pharm. Sci., 2016. 105(2): p. 697-704. 
38. Stärtzel, P., Arginine as an Excipient for Protein Freeze-Drying: A Mini Review. J. Pharm. Sci., 
2018. 107(4): p. 960-967. 
39. Tsumoto, K., et al., Role of Arginine in Protein Refolding, Solubilization, and Purification. 
Biotechnol. Prog., 2004. 20(5): p. 1301-1308. 
40. Hackl, E., et al., Effect of Arginine on the Aggregation of Protein in Freeze-Dried Formulations 
Containing Sugars and Polyol: 1—Formulation Development. AAPS PharmSciTech, 2018. 19(2): 
p. 896-911. 
41. Izutsu, K.-I., et al., Effect of counterions on the physical properties of l-arginine in frozen 
solutions and freeze-dried solids. Int. J. Pharm., 2005. 301(1–2): p. 161-169. 








Method development and analysis of the water content of the maximally freeze concentrated 





Method Development and Analysis of the Water Content of the 
Maximally Freeze Concentrated Solution Suitable for Protein 
Lyophilisation 
 
The following chapter has been published as research article in the European Journal of Pharmaceutics 
and Biopharmaceutics and appears in this thesis with the journal’s permission: 
 
Ivonne Seifert, Alessandro Bregolin, Davide Fissore, and Wolfgang Frieß 
Method Development and Analysis of the Water Content of the Maximally Freeze Concentration 
Solution Suitable for Protein Lyophilisation 
Eur. J. Pharm. Biopharm. 153 (2020), 36-42 
 
The supplementary data was inserted into this chapter. 
 
Abstract 
During freeze-drying of a liquid formulation, a freeze-concentrate is formed in the first phase, the 
freezing step. Understanding the composition of the maximally freeze concentrated solution can help 
to judge the process stability of biopharmaceuticals during lyophilisation. Our objective was to develop 
a suitable method to determine the water content of the maximally freeze concentrated solution using 
differential scanning calorimetry (DSC). Three different methods were compared: (i) the intercept of 
the glass transition temperature of the maximally freeze concentrated solution Tg’ and the melting 
temperature Tm for a concentration series, (ii) the linear regression of the melting enthalpy starting 
from the onset of Tg’ until the end of the melting event for a concentration series, and (iii) a one-point 
determination of the amount of unfrozen water. While Method 1 is accurate but requires the analysis 
of a high number of samples, Method 3 requires only one single sample, with a loss of accuracy. 
Method 2 works best taking sample preparation and accuracy into account. Various systems 






chloride, arginine hydrochloride, arginine citrate) were evaluated with different antibody 
concentrations to evaluate the composition of the maximally freeze concentrated solution. The freeze 
concentrates exhibited a water content of 20 - 30%, slightly dependent on the excipients, but 
independent of the antibody concentration. The methodology we developed is broadly applicable for 
the analysis of the composition of maximally freeze concentrated solutions and can help to elucidate 
protein stability during lyophilisation. 
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Method development and analysis of the water content of the maximally freeze concentrated 




Table of Contents 
Abstract ..................................................................................................................................... 33 
1. Introduction........................................................................................................................ 36 
2. Materials and Methods ....................................................................................................... 38 
2.1 Materials ................................................................................................................................ 38 
2.2 Methods ................................................................................................................................ 38 
2.2.1 Determination of wg’ ..................................................................................................... 38 
2.2.1.1 Differential scanning calorimetry (DSC) .................................................................... 38 
2.2.1.2 Calculation of wg’ ....................................................................................................... 39 
2.2.1.2.1 Method 1: Intercept of Tg’ and Tm curves ........................................................... 39 
2.2.1.2.2 Method 2: Linear regression ............................................................................... 39 
2.2.1.2.3 Method 3: Single sample determination ............................................................. 39 
2.2.2 Determination of wg’ in ternary and higher systems .................................................... 40 
3. Results and Discussion ........................................................................................................ 41 
3.1 Evaluation of methods to determine a maximally freeze concentrated system .................. 41 
3.2 Wg’ in protein containing samples ........................................................................................ 44 
4. Conclusion .......................................................................................................................... 47 
Acknowledgement ..................................................................................................................... 48 









Cooling of aqueous solutions below the freezing temperature leads to formation of ice. The 
crystallisation of ice corresponds to a removal of water from the system and an up-concentration of 
all solutes remaining in the unfrozen phase. This process is known as freeze concentration. During 
freeze drying of biological material or biopharmaceuticals, freeze concentration affects the behaviour 
of the proteins through solute concentration, potential crystallisation of buffer components 
accompanied by a pH shift, phase separation, increased viscosity, increased ionic strength, or 
interfacial stress [1-7]. An increased viscosity during freezing can lead for example to phase separation 
with a protein-rich phase, potentially lacking stabilising excipients [2, 4, 8]. On the other hand, reaction 
rates can be reduced with increased viscosity [9, 10]. A pH shift through buffer component 
crystallisation and increased ionic strength can change the protein-protein interactions [11, 12]. 
Additionally, freeze concentration is accompanied with both thermodynamic and kinetic changes 
causing either stabilisation or destabilisation of a protein. It also need to be kept in mind that since 
freeze concentration continues until ice formation is complete and that therefore protein perturbation 
occurs over a longer time frame [13].  
The freeze concentrated solution is defined by the mass fraction of solids wg’ and the mass fraction of 
unfrozen water wuf [14]. Wuf and wg’ can be determined by techniques such as cryoscopy and 
differential scanning calorimetry (DSC). Another approach is to follow the phase change state via the 
product temperature during ice nucleation within the freeze drying itself [14-20].  
Different methods are described in literature to calculate wg’ using DSC. One approach is to measure 
a single sample. The amount of frozen water in the sample can be calculated from the ice melting 
endotherm by taking reference to the ice melting endotherm of pure water. Finally, wg’ can be 
obtained based on the total solid content of the solution via the amount of unfrozen water  [21, 22]. 
Typically, the melting enthalpy of pure water is compared with the melting enthalpy of a 20% w/w 
solution. For sucrose, trehalose, and glycerol wg’ can be 64%, 83%, and 54%, respectively [21]. A wg’ of 
68% for glycerol results if using a stepwise evaluation of the apparent melting heat and calculating the 
ice fraction. Thereby, the sample temperature is alternated in a series of heating and isothermal steps 
[23]. Different wg’ values for different solid contents are observed for this type of one point 
determination [24]. Since ice vitrification might not be completed after a simple freezing step, 
annealing should be applied. By this a higher sucrose wg’ of 81% (w/w) is obtained [25]. 
In contrast to a one point determination method, two approaches using intercepts of fits are possible 
to determine wg’ based on a concentration dependent phase diagram (Figure 3-1). Literature is divided 
over the glass transition temperature of the maximally freeze concentrated solution, stating two 
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transitions as Tg’ and Tg’’. The Gordon-Taylor equation can be used to fit exemplarily the glass transition 
of sucrose-water mixtures at different ratios. The intercept of the Tg curve as a function of sucrose 
concentration and Tg’’ at approx. -45°C for sucrose renders wg’. Alternatively, the intercept of the 
melting temperature (Tm) as a function of sucrose concentration curve and Tg’ at approx. -34°C for 
sucrose leads to wg’. For sucrose a wg’ of 81 - 83% (w/w) results with both methods [26-31]. For 
trehalose different wg’ values, ranging from 70% to 83% (w/w), are reported [32, 33].  
 
Figure 3-1: Schematic phase diagram, adapted from [14]. 
 
Furthermore, a linear function of the ice melting enthalpy against the solid concentration can be 
extrapolated to ΔH = 0 J/g to obtain wg’ [34-36]. This is a simple method without the need for major 
mathematical theories. Thereby, a wg’ of sucrose of 79% (w/w) results [34]. Thus, overall rather 
different wg’ values are reported for sucrose ranging from 64% [21, 37], 77% [29], up to 82% [25, 26, 
38] and for trehalose ranging from 71 to 83% [32, 33]. Other reported wg’ values of excipients relevant 
for freeze-drying are 46% for polyethylene glycol 40000, which increased with the addition of sucrose 
at a 1:1 ratio to 60% [39], and 81% (w/w) for citric acid [40]. 
Wg’ is currently not considered, when it comes to freeze drying of proteins. Knowing the exact 
composition can help to prepare the freeze concentrates and study e.g. protein-protein interactions 
or protein stability excluding ice-freeze concentrate interface effects. To answer these questions and 
due to the substantial deviation of wg’ values stated in literature, the aim of this study was to evaluate 






(i) using the intercept of the Tg’ and Tm curves; (ii) using a linear regression of the melting endotherm; 
and (iii) using a one point measurement of the frozen water based on the melting endotherm. The 
methods were to be evaluated with respect to accuracy and effort. Subsequently the wg’ of different 
formulations relevant for lyophilisates of biopharmaceuticals was to be analysed. Besides sugar and 
protein also buffers, amino acids, and NaCl as excipients were evaluated. 
 
2. Materials and Methods 
2.1 Materials 
Sucrose, L-histidine base, L-histidine monohydrochloride, L-arginine base, and L-arginine 
hydrochloride monohydrate (ArgHCl) were purchased from Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany. Sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, citric 
acid anhydrous, and sodium chloride were obtained from VWR International, Ismaning, Germany. All 
samples were prepared with highly purified water (HPW; Sartorius Arium Pro, Sartorius, Göttingen, 




2.2.1 Determination of wg’ 
2.2.1.1 Differential scanning calorimetry (DSC) 
Tg’ and Tm were determined with a Netzsch Polyma 214 (Netzsch, Selb, Germany), a DSC 821e (Mettler 
Toledo, Gießen, Germany), a TA Discovery (TA Instruments, New Castle, DE, USA), and a TA Q2000 (TA 
Instruments) under N2 atmosphere. Low concentration samples are difficult to determine due to a high 
requirement for sensitivity and therefore different instruments were explored. 15 - 25 µL solution with 
0% up to 65% (w/w) solid content was weighted into aluminium crucibles and sealed hermetically. The 
samples were cooled from 20°C to -60°C (-40°C only for Netzsch) at 5°C/min, reheated to -30°C at 
2°C/min, held for 1 h to ensure complete ice formation [29], cooled to -60°C (-40°C only for Netzsch) 
at 5°C/min, and finally heated to 20°C at 2°C/min. Calibration was performed with indium as provided 
by the manufacturer. Netzsch Proteus Analysis, Mettler STARe, TRIOS, and TA Universal Analysis 
software were used for data analysis. The specific heat capacity of water (ΔCp) was evaluated with a 
tangential step before and after the ice melting in a pure HPW sample. The melting enthalpy (ΔH) was 
evaluated by an integration starting from the beginning of the Tg’ endothermal shift and ending at the 
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return to baseline after the melting event. Sigmoidal or spline baseline settings were used for the 
integration. 
 
2.2.1.2 Calculation of wg’ 
2.2.1.2.1 Method 1: Intercept of Tg’ and Tm curves 
Values of Tm vs. the relative solid content (x) were fitted to the Chen model (Equation (1)), an extension 
of the Clausius-Clapeyron equation [31] with Tm and Tw being the melting temperature of sample and 
HPW, respectively, β the molar freezing temperature constant for water (1860 kg∙K/mol), M the molar 
mass of water. B and E were fitted to the experimental data with OriginPro 2018. The onset 
temperature of Tg’ was fitted as horizontal line. Wg’ was determined as the intercept of the Tm curve 
and the onset temperature of Tg’ line. 
Equation (1) 




1 − 𝑥 − 𝐵𝑥
1 − 𝑥 − 𝐵𝑥 + 𝐸𝑥
 
 
2.2.1.2.2 Method 2: Linear regression 
The obtained DSC thermograms were integrated from the onset temperature of Tg’ until the end of 
the melting peak with a sigmoidal baseline type to obtain the melting enthalpy ΔH. A linear regression 
function of the ice melting enthalpy against the solid concentration was extrapolated to ΔH = 0 J/g to 
calculate wg’. 
 
2.2.1.2.3 Method 3: Single sample determination 
The effective fusion enthalpy of ice in solution Le was calculated from the specific heat coefficient ΔCp, 
Tm and Tw (Equation (2)). The amount of frozen water wf (Equation (3)) is obtained from the melting 
enthalpy of the sample ΔHs, the sample mass ms filled in the pan, the melting enthalpy of water ΔHw 
and Le (adapted from [24] including the assumptions of neglectable effects of the ice melting enthalpy 
on the temperature and heat dilution). Finally, wg’ is calculated sample dependent with the solid 
content (solute concentration cs and sample mass ms), the total water content wtotal and wf 
(Equation (4)). 
Equation (2) 














𝑐𝑠 ∙  𝑚𝑠
(𝑊𝑡𝑜𝑡𝑎𝑙 − 𝑊𝑓) + 𝑐𝑠 ∙ 𝑚𝑠
 
 
2.2.2 Determination of wg’ in ternary and higher systems 
The compositions tested are listed in Table 3-1. Arginine citrate (ArgCitr) powder (residual moisture 
5.35%) was produced by spray drying (Mini Spray Dryer B-290, Buchi, Essen, Germany) an arginine 
citrate solution pH 6.0. An 8% (w/w) solution was spray dried at 140°C inlet temperature, 81°C outlet 
temperature, 70% aspiration, 600 L flow, and 10% pump speed. mAb was dialysed against the 
individual buffers or HPW with a 10-fold buffer exchange in Vivaspin® 20 Ultrafiltration Uni (30 kDa, 
Sartorius, Goettingen, Germany) and upconcentrated if necessary.  
The formulations were prepared at consistent solute ratios but different total solid content ranging 
from 10% up to 50% w/w.  
 
Table 3-1: Formulations used for DSC experiments to evaluate wg’. The ratios of different excipients including 
sugar and buffer to mAb are stated in italic. The formulations were prepared at consistent solute ratios ranging 
fom 10% up to 50% w/w solid content. 
Abbreviation Formulation Sugar Buffer Further excipient mAb 
Suc Sucrose 7 -- -- 0, 0.2, 1, 5, 20 
Suc+His 5.3 Sucrose + Histidine pH 5.3 7 0.23 -- 0, 0.2, 1 
Suc+His 7.4 Sucrose + Histidine pH 7.4 7 0.23 -- 0, 0.2, 1 
Suc+Phos 5.3 Sucrose + Phosphate pH 5.3 7 0.15 -- 0, 0.2, 1 
Suc+Phos 7.4 Sucrose + Phosphate pH 7.4 7 0.15 -- 0, 0.2, 1 
Suc+0.4NaCl Sucrose + NaCl 7 -- 0.4 0, 0.2, 1 
Suc+0.8NaCl Sucrose + NaCl 7 -- 0.8 0, 0.2, 1 
Tre Trehalose 7 -- -- 0, 0.2, 1, 10 
ArgCitr Arginine citrate -- -- 5 -- 
ArgHCl Arginine*HCl -- -- 5 0, 0.2 
NaCl NaCl -- -- 0.4 1 
mAb mAb -- -- -- pure 
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3. Results and Discussion 
3.1 Evaluation of methods to determine a maximally freeze concentrated 
system 
The first aim of this study was to identify the most suitable method to determine wg’ of a maximally 
freeze concentrated system balancing accuracy and sample and time consumption. 1.5% up to 
65% (w/w) sucrose solutions were analysed using three methods. 
The first method makes use of the intercept of two curves. The first curve represents the linear fit of 
the onset of Tg’. The second curve reflecting the Tm peak is fitted with the Chen model, adapted from 
the Clausius-Clapeyron equation [31, 41] resulting in B and E of 0.056 ± 0.0063 and 
8.19∙10-5 ± 9.84∙10-6, respectively. The Tm curve and Tg’ onset temperature (around -34°C) complies 
with literature data [42, 43]. The intercept of the two curves reflects wg’ (Figure 3-2). Method 1 results 
in 77.4 ± 1.7% sucrose in the maximally freeze concentrated system. 
 
 
Figure 3-2: Determination of wg’ in a sucrose-water mixture using the intercept of the experimental evaluated 
Tm peaks (squares) fitted with the Chen model corresponding to Equation (1) and the onset of the corresponding 
Tg’ (dots) fitted as horizontal line. 
 
Method 2 utilises the solute concentration dependent change in the melting enthalpy to obtain wg’. 
The DSC thermogram is integrated for ΔH starting at the onset of Tg’ until the end of the melting event 
(Figure 3-3). The linear fit of ΔH is extrapolated to 0 J/g, which reflects the freeze concentrated state 







Figure 3-3: Exemplary DSC trace of 62% sucrose with ΔH integrated starting from the onset of Tg’ until the end of 
the melting event. 
 
 
Figure 3-4: Determination of wg’ in a sucrose-water mixture using the change in melting enthalpy. 
 
The third method directly calculates wg’ (Figure 3- 5B) from the amount of frozen water of a specific 
sample obtained from the DSC melting enthalpy (Figure 3-5A). The experimental ΔCp of 
2.10 ± 0.01 J/gK, Tw of 0.4 ± 0.3°C, and ΔHw of 347 ± 2 J/g are in agreement with the literature values 
of 2.06 J/gK, 0°C, and 333 J/g, respectively [44, 45]. An exemplary thermogram can be found in 
Figure 3-6. This method results in wg’ for sucrose of 77.0% in the freeze concentrated state. The frozen 
water content could be determined with low standard deviation independent of the sugar 
concentration. But the small error in the amount of unfrozen water at low concentration samples led 
to high standard deviations in the calculated wg’. Sugar concentrations of 30% and higher prompted 
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reliable wg’ values with a low standard deviation. Thus, 3.5% (w/w) sucrose resulted in a wg’ of 
79.3 ± 10.6%, whereas 62% (w/w) sucrose showed a wg’ of 77.7% ± 0.2%. But these high solid contents 
are not used in lyophilisation of parenteral products.  
 
 
Figure 3-5: A: Frozen water content obtained from the melting enthalpy in a sucrose-water mixture and B: 








Figure 3-6: DSC thermogram of HPW obtained from Mettler DSC 821e. 
All three tested methods resulted in a narrow range of wg’ values of 75.4 – 77.4%, whereas literature 
stated wg’ values between 64% and 83% [21, 25, 27, 29, 34]. Comparing the three methods, the first 
method is the most accurate since it requires only the evaluation of temperatures without integration 
of thermograms. However, a rather high number of samples with high solid content needs to be 
prepared and analysed, which is time consuming. This is mandatory to apply the Chen model to fit Tm 
and a new fit is required for each formulation. Considering poorly soluble excipients or rather high 
concentrations of proteins like antibodies, this method has its limitations. The second method could 
be used with less, at least five different concentrations preferably between 5% and 45%, for a simple 
linear fit of the melting enthalpy (same result for wg’ with p < 0.05 according to t-test). The third 
method is an even further simplification using only one single sample with a solid content of 30% or 
higher. With lower solid content, the error becomes inacceptable. Analysis of only one higher 
concentration sample showed more reliable results but still differed from the mean. DSC systems with 
higher sensitivity might be used with lower solid contents rendering method 3 superior. Overall, 
method 2 is the most applicable approach taking sample number and therefore measurement time, 
calculation of wg’, and reliability of the results into account. Method 2 was therefore subsequently 
used to analyse the wg’ of different formulations.  
 
3.2 Wg’ in protein containing samples 
Subsequently method 2 was used to evaluate wg’ of sucrose and trehalose based formulations. The 
effect of histidine buffer and phosphate buffer at pH 5.3 and 7.4 as well NaCl was tested. In addition, 
the influence of the mAb concentration on the composition of the freeze concentrate was studied 
considering up to 200 g/L protein formulations. Furthermore, sugar free systems based on arginine 
hydrochloride, arginine citrate, and sodium chloride as sole excipient were tested with and without 
mAb. 
Adding mAb to sucrose at different ratios up to Suc:mAb 7:20 did not impact wg’, with values between 
74.3% and 78.0% for different mAb concentrations and 75.2 ± 0.8% for pure sucrose. mAb addition did 
not lead to a change in wg’ of the system (Figure 3-7). In addition, we could show that buffer did not 
significantly lower wg’ of Suc + His 5.3 (wg’ of 73.1 ± 1.6%), Suc + His 7.4 (73.8 ± 1.4%), Suc + Phos 5.3 
(72.9 ± 1.2%), and Suc + Phos 7.4 (73.6 ± 1.5%). Addition of salt resulted in a decrease of wg’ of freeze 
concentrates to 72.4 ± 2.3% and 70.4 ± 2.0% for Suc + 0.4 NaCl and Suc + 0.8 NaCl as found by Her et 
al. [46]. NaCl alone without further excipient with mAb crystallised during the freezing and annealing 
process in the DSC. The eutectic concentration of NaCl-water is composed of 23.3% (w/w) NaCl [47]. 
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Therefore, the integration was performed starting at the beginning of the eutectic temperature until 
the end of the melting event. Wg’ of crystallised NaCl and mAb at a 0.4:1 ratio was 67.7 ± 3.4%, which 
was significant lower compared to the system Suc + 0.4 NaCl containing sucrose:NaCl:mAb in a ratio 
of 7:0.4:1 (p < 0.05, t-test).  
 
 
Figure 3-7: Wg’ results of different sugar-based systems with varied mAb concentrations.  
 
Trehalose as alternative disaccharide rendered a wg’ similar to sucrose with 73.0 ± 2.7%. Crystallisation 
of trehalose can occur in case of annealing and thereby influencing wg’ [48]. DSC thermograms did not 
indicate crystallisation. Again, the addition of histidine buffer pH 5.3 to the sugar did not affect wg’. 
Sugar-free formulations based on L-arginine may present an alternative for freeze-drying of protein 
drugs [49]. Other than sugar, arginine does not promote preferential exclusion in the solution to be 
freeze dried. Arginine is able to form hydrogen bonds with protein molecules and undergoes ion-dipole 
interactions [50], which might affect wg’. Arginine hydrochloride can reduce protein-protein 
interactions, which can lead to a significant reduction in viscosity at high concentrations [51]. Such high 
concentrations are expected for protein containing freeze-concentrates. ArgCitr, ArgHCl, and ArgHCl 
with mAb (ArgHCl:mAb 5:0.2) showed wg’ values of 79.6 ± 3.1%, 72.4 ± 2.0% and 72.7 ± 2.3%, 
respectively. Due to the Tg’ and Tg increasing influence of citric acid, wg’ of ArgCitr might be influenced 
[52]. 
Subsequently the wg’ of the mAb and its potential effect in mixtures with excipients was analysed. 






estimated to be at around -15°C [53]. According to the onset of the melting peak in the thermograms 
(drop in baseline) the onset temperature of Tg’ could be approximated to be around -25°C ranging from 
0.2% mAb up to 30% mAb (Figure 3-8). The obtained wg’ of pure mAb was 80.8 ± 3.4%.  
 
Figure 3-8: Exemplary DSC thermogram of 19% mAb in HPW. Estimation of Tg’ onset is depicted in the zoom. The 
onset of Tg’ at about -25°C was used as starting point for the integration of the melting event. 
 
With the determined wg’ values, the composition of the maximally freeze concentrate can be 
calculated taking the initial solid content of the formulation into account. Other than the solid content 
at the concentration of wg’ only unfrozen water remains. The wg’ of mAb-sugar mixtures was 
independent of the mAb concentration. However, increasing the mAb concentration results in 
different mAb to sugar or excipient ratios in the freeze concentrate. Table 3-2 states some examples 
with different mAb to sucrose ratios, ranging from low to high mAb concentrations. A formulation with 
20% mAb will result in around 56% (w/w) mAb in the concentrated state with only 22% (w/w) H2O and 
20% (w/w) sucrose.  
 
Table 3-2: Exemplary freeze concentrate compositions. Ratios of solids in starting liquid upconcentrated to the 
total solid content wg’. H2O in the concentrated state is synonymous with unfrozen water. 
wg’ 
[%] 










mAb [%] H2O [%] 
74.3 7 -- 0.2 92.8 72.2 -- 2.1 25.7 
72.4 7 0.23 1 92.0 61.6 2.0 8.8 27.6 
78.0 7 -- 20 73.0 20.2 -- 57.8 22.0 
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Histidine buffer resulted in a marked decrease in ionic strength of 275 mM to 156 mM with increasing 
pH values. Phosphate buffer increased in ionic strength to 302 mM and 391 mM for a pH of 5.3 and 
7.4, respectively. NaCl caused an enormous increase in ionic strength in the freeze concentrated to 
1.4 M. The high ionic strength in NaCl-containing samples could possibly influence the system by 
decreasing Tg’ and thus wg’ [14]. However, wg’ was influenced neither by different sugar 
concentrations, differences in ionic strength nor the mAb concentration. No systematic analysis of wg’ 
with different mAb containing formulations has been stated so far. The up-concentration of proteins 
can lead to an increase in attractive protein-protein interactions or phase separation with a loss in 
stabilising protein-excipient interactions. These effects in combination with high ionic strength could 
foster potential protein instability [4, 7].  
Furthermore, the freeze concentrate was also determined to be between 72.4% and 79.6% in sugar 
free arginine systems. Crystallisation of NaCl as sole excipient resulted in slightly lower total solid 
content with around 67.6% in the up-concentrated state, which was significant lower compared to 
amorphous matrix forming systems. 
 
4. Conclusion 
Different DSC methods were previously reported in literature to determine the amount and the water 
content of the maximally freeze concentrated solution formed upon freezing solutions [24, 31, 35]. 
Knowledge of the composition can help to judge protein drug instability during freeze-drying and can 
enable to prepare the freeze concentrate and analyse its properties. We evaluated three different 
approaches for analysis of the freeze concentrate composition. Using the intercept of concentration 
dependent Tg’ and Tm curves requires a large number of samples with different total solid content and 
samples of high total solid content of >30%. The high number of different samples results in an 
accurate result for the composition of the freeze concentrate. Analysis of the frozen water content and 
with that wg’ of only one sample is rather limited and dependent on the total solid content and the 
sensitivity of the DSC system. Higher solid contents are recommended for this method. A very good 
compromise is to determine the frozen water content of samples of 10 – 30% solid content based on 
the AUC of the melting event and to extrapolate. This method renders reproducible results with little 
sample and time consumption. 
Overall, the total solid content wg’ of the maximally freeze concentrated solution of sugar based 
amorphous protein solutions lays between 70% and 80% total, regardless the different additional 






The mAb concentrations did not affect wg’. Sugar free arginine formulations show similar wg’ values 
between 70% and 80%.  
The process of freeze concentration leads to increased viscosities, potential crystallisation of solutes, 
phase separation, or high ionic strengths [2, 4, 7]. Thereby, increased protein concentration is 
accompanied by more protein-protein interactions. Eventually, the combination with pH shifts due to 
buffer crystallisation or high ionic strength can force protein instabilities. In following studies, freeze 
concentrates of different formulations will be produced and protein stability evaluated accordingly.  
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During freeze drying of biologics, a highly viscous freeze concentrate (FC) is formed upon the initial 
freezing due to the crystallisation of ice. Protein stability in this freeze concentrated phase is not yet 
well understood, but can decide upon the success of the lyophilisation itself. Protein stability may be 
high below the Tg’ as it is typically the case during primary drying but decreases above Tg’, e.g. during 
annealing or during aggressive freeze drying above Tg’ in presence of a crystalline bulking agent or, 
beyond freeze drying, during storage of frozen bulk. Different FCs containing monoclonal antibody, 
sucrose, histidine or phosphate buffer and sodium chloride were prepared via partial freeze drying and 
analysed for protein aggregation. No solute crystallisation is visible and the systems are vitrifying 
during cooling. Increasing sugar or buffer concentration showed positive effects on either melting and 
aggregation temperature or on protein self-interaction as indicated by A2 values. Protein integrity in 
the FC was not affected by 1 month storage at temperatures above Tg’. Thus, upconcentration of 
solutes during freezing does not negatively impact protein stability. Exceeding Tg’ during freeze drying 
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Freeze drying is the method of choice to stabilise therapeutic proteins if stability in liquid form is not 
adequate [1]. Thereby, the product undergoes drastic physical changes in the initial freezing step 
before ice sublimation starts [2-4]. During freezing, crystallisation of ice leads to an increase in solute 
concentration remaining in the unfrozen phase, the freeze concentrate (FC). With decreasing 
temperature, viscosity increases per se and even more pronounced with the increase in solute 
concentration. This higher viscosity may improve colloidal protein stability reducing reaction rates [4-
6].  
Phase separation may occur rendering a protein-rich phase, in which protein stability is potentially 
lowered due to a depleted ratio of stabilising excipient to protein [7-9]. As the concentration of charged 
solute goes up during concentration, ionic strength increases eventually leading to charge shielding 
and enhanced attractive protein self-interaction. This can be accompanied by a loss in protein stability 
[10, 11]. At the same time, the increase in protein concentration gives rise to colloidal instability [12-
15]. However, in the freeze concentrated state, reaction rates for protein unfolding as well as mobility 
become reduced due to an increase in viscosity and proteins in high concentration behaving as 
polymers [2, 16, 17]. Furthermore, a pH shift of the system as a function of temperature, in extreme 
cases drastically enhanced by preferential crystallisation of buffer components can alter protein 
stability [1, 18-20]. Phosphate buffers may show a downward shift of up to 4 pH units [18, 21] and 
succinate buffers an increase with decreasing temperature [22]. Furthermore, proteins can undergo 
freezing stresses such as cold denaturation depending on pH, protein concentration, and excipients 
[23]. In addition to a potentially reduced protein stability in the concentrating solution, protein can 
enrich, unfold and aggregate at the ice-liquid interface [24, 25]. The mechanism of cold denaturation 
is potentially enhanced by the molecules in the quasi liquid layer between the ice and the freeze 
concentrated phase [26, 27]. The product cooling and the freezing rate of the system once nucleated 
render different rates of ice formation, ice crystal and interface area sizes affecting potential protein 
damage [23, 28-33]. At the end of freezing, when all ice has crystallised [29], a FC with an enormous 
high total solid content has formed. The maximally freeze concentrated solution of sucrose consists of 
around 70% to 80% (w/w) solids, termed wg’, and 20% to 30% (w/w) unfrozen water [34-38]. Thus, the 
sucrose concentration in the FC is above the solubility level of sucrose (0.5 g/ml [39]) at room 
temperature.  
Aim of our study was to better understand protein behaviour in the FC and the risk of protein instability 
during annealing or aggressive collapse drying cycles coming with product temperatures above the 
glass transition temperature of the maximally freeze concentrated solution (Tg’) and even storage of 
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frozen bulk. Direct analysis of protein stability in the FC is challenging since the FC itself is difficult to 
obtain. Petzold et al. described freezing of a sucrose solution to -20°C and separation of the FC from 
the ice formed using a suction unit similar to a filter flask at ambient temperature [40]. Similarly, a 
protein solution frozen to -10°C may be centrifuged with the FC accumulating at the bottom [41]. In 
need for a simple preparation method without separating the FC from the ice interface, we developed 
a method based on partial freeze drying. With the FC in hand, we evaluated the influence of the high 
solutes and protein concentration on protein stability. Protein self-interaction was analysed for a mAb 
with increased sucrose, buffer, and salt levels. As the analysis in the FC was not always possible, 
comparable concentrated solutions were used for interaction studies. Ultimately, the protein 
aggregation as function of time and temperature reflecting freeze drying with sucrose as stabiliser with 
histidine and phosphate buffer pH 5.3 and pH 7.4 was analysed, followed by an evaluation of the effect 
of NaCl expressing potentially present additional ionic species in a lyophilised formulation [42]. 
 
2. Materials and Methods 
2.1 Materials 
Sucrose, L-histidine base, L-histidine hydrochloride monohydrate, sodium phosphate dibasic 
dihydrate, and sodium phosphate monobasic dihydrate were purchased from Merck KGaA, Darmstadt, 
Germany, sodium chloride from VWR International, Ismaning, Germany, and D-(+)-trehalose dihydrate 
from Pfanstiehl Technologies, Waukegan, IL, USA.  
A rather hydrophobic monoclonal IgG1 antibody without specific pharmaceutically relevant target 
(94 mg/ml, MW ca. 148 kDa, ϵ = 1.37 mL/mg∙cm, referred to as mAb) in 15 mM histidine buffer pH 5.3 
was used as model protein. mAb used for stability analysis was dialysed against highly purified water 
(HPW) in a 33 mm dialysis tubing cellulose membrane (14 kDa cut-off, Merck KGaA). 20 mL mAb were 
dialysed against 5 L HPW with a 3-times media exchange. Concentration was determined via UV 
absorption (Nanodrop 2000, ThermoFisher Scientific, Waltham, MA, USA). Formulations were filtrated 
with 0.2 µm polyethersulfone (PES) membrane syringe filters (VWR International) prior to use. 
 
2.2 Methods 
2.2.1 Freeze-Thaw (FT) 
Freeze-thaw experiments were performed using an Epsilon 2-6D freeze drier (Martin Christ, Osterode 






isothermal hold for 3 h, thawed back to 20°C at a ramp of 1°C/min followed by an isothermal hold of 
3 h. This cycle was repeated three times. Thermocouples confirmed complete ice crystallisation and 
thawing in selected vials by reaching -50°C and 20°C, respectively. 
 
2.2.2 Preparation of freeze concentrates 
For the preparation of freeze concentrates (Figure 4-1) solutions with an already approx. 4x increased 
starting total solid content based on 30% (w/w) sucrose were filled in DIN 10R Vials (Fiolax®, Schott 
AG, Mainz, Germany). The vials were semi-stoppered with lyophilisation stoppers (igloo stoppers with 
B2-TR coating, West Pharmaceutical Services, Eschweiler, Germany). The formulations were partially 
freeze dried in an Epsilon 2-6D freeze drier (Martin Christ, Osterode am Harz, Germany). After freezing 
to -50°C at 1°C/min and 1 h hold time, freeze drying was performed at -5°C at 0.1 mbar until 
comparative pressure measurement with Pirani and capacitance sensor aligned. The weight of the vial 
was recorded prior to and after freeze drying. Water was added to match the solid and water content 
of the FC as determined previously (Table 4-2) [34] and the vial equilibrated 2 to 24 hours at 2 – 8°C. 
FCs tested in a 1-month stability study at 25°C, -10°C, and -80°C are listed in Table 4-1.  
 
Table 4-1: FCs tested in a 1 month stability study. Numbers reflect the ratios of different excipients including 
sugar and buffer to mAb. 
 Base formulation for FC reflecting the solute ratios 
Formulation Sucrose Buffer NaCl mAb 
Suc 7 - - 0, 0.2, 1 
Suc + His 5.3 7 0.23 - 0, 0.2, 1 
Suc + His 7.4 7 0.23 - 0, 0.2, 1 
Suc + Phos 5.3 7 0.15 - 0, 0.2 
Suc + Phos 7.4 7 0.15 - 0, 0.2 
Suc + 0.4 NaCl 7 - 0.4 0, 0.2, 1 
Suc + 0.8 NaCl 7 - 0.8 0, 0.2, 1 
 
  
Freeze Concentration during Freezing: How does the Maximally Freeze Concentrated Solution 




Table 4-2: Composition of FCs with different mAb concentrations in % w/w according to [32]. 




























































































Approximately 0.3 ml samples were loaded between two parallel plates (upper plate 25 mm diameter) 
with a gap of 0.5 mm in a rheometer MCR 100 (Anton Paar, Graz, Austria). During a temperature range 
from 20°C to -15°C with -2°C/min viscosity was measured at a shear rate of 300 1/s. The diffusion 
coefficient D of the mAb was calculated based on the Stokes-Einstein equation [43]. 
 
2.2.4 Dynamic light scattering (DLS) 
For DLS analysis, samples with 2 – 20 mg/ml mAb were centrifuged at 10,000 xg for 10 min and 20 µl 
filled in a 364 well plate (Corning, Corning, NY, USA). The plate was centrifuged at 546 xg for 2 min 






measured on a DynaPro plate reader III (Wyatt Technology, Santa Barbara, CA, USA) using 
10 acquisitions of 5 s at 25°C. The autocorrelation function, the mutual diffusion coefficient, and the 
polydispersity index were determined with the Dynamics V7.8 software. The interaction parameter kD 
was calculated from the mutual diffusion coefficient and transferred to A*2 based on the TIM-equation 
[11]. All DLS measurements were performed in 6 replicates per sample. 
 
2.2.5 Composition-gradient multi-angle light scattering (CG-MALS) 
10 mg/ml mAb in 15 mM histidine buffer pH 5.3 and 0% to 5% (w/w) sucrose samples were used for 
CG-MALS measurement. Before use, all samples were filtrated with 0.2 µm PES filters. Light scattering 
and protein concentration were analysed with an automated CG-MALS instrument equipped with a 
dual syringe-pump Calypso-II sample and preparation unit, a Dawn Heleos-II multi-angle laser light 
scattering detector, and an Optilab® T-rEX dRI detector (Wyatt Technologies). Calypso 2.1.5 software 
was used to obtain Zimm Plots and A2 values [44]. 
 
2.2.6 nanoDSF® 
NanoDSF was used to study thermal unfolding of the mAb in different formulations. The samples were 
filled in standard glass capillaries and sealed afterwards. A Prometheus® NT.48 (NanoTemper 
Technologies, Munich, Germany) was used starting from 25°C up to 95°C or 110°C at a ramp of 
1°C/min. Intrinsic protein fluorescence intensity at 330 nm and 350 nm was measured after excitation 
at 280 nm (± 10 nm). Furthermore, back-reflection intensity was measured to detect protein 
aggregation and precipitation. The fluorescence intensity ratio (FI350/FI330) was used to determine 
protein thermal unfolding, calculated by PR.ThermControl V2.1 software (NanoTemper). 
 
2.2.7 Light obscuration 
Subvisible particles were characterised by light obscuration. The freeze concentrates were diluted with 
HPW to 7% (w/w) sucrose and analysed using a PAMAS SVSS-C35 particle counter with an HCB-LD-
25/25 sensor (Partikelmess- und Analysensysteme GmbH, Ruthesheim, Germany). The system was 
rinsed with HPW followed by a sample pre-rinse of 0.2 ml. Samples were analysed 4 times with 0.2 ml 
each [45]. 
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2.2.8 Size exclusion chromatography (SEC) 
SEC was performed with an Agilent 1100 series HPLC system equipped with a UV/Vis detector 
measuring at 280 nm (Agilent Technologies, Santa Clara, CA, USA). A Waters AQUITY UPLC Protein BEH 
200Å column (1.7 µm; 4.6 x 150 mm; Waters GmbH, Eschborn, Germany) was used with a 50 mM 
sodium phosphate and 400 mM sodium perchlorate buffer at pH 6.0 at 0.4 ml/min. All samples were 
diluted to 2 mg/ml mAb and centrifuged at 7,000 rpm for 10 min prior to use. The area under the peaks 
as well as relative areas of monomer, fragments, and aggregates were determined after blank 
subtraction using ChemStation software (Agilent Technologies). 
 
3. Results and Discussion 
3.1 FC properties 
For preparation of FCs partial freeze drying was performed, interrupting the process in the course of 
primary drying to reach a water level of slightly less than what was determined by DSC previously [34] 
followed by adjustment to the final water content. Regardless of the composition, all FCs were 
transparent with some air bubbles entrapped, highly viscous and solidified solute, ice crystals, or phase 
separation were not noticeable (Figure 4-1). Due to the collapse upon partial freeze drying and further 
viscosity increase, mAb containing FCs had a more foam-like appearance. No ice or solute 
crystallisation but only vitrification was observed when cooling the FCs to -80°C. Furthermore, the 







Figure 4-1: Visual appearance of exemplary FCs. 
 
The sucrose FCs showed a viscosity of 2.5 Pa∙s at 20°C (Figure 4-2). In comparison, the viscosity of a 
7% (w/w) and 20% (w/w) sucrose solution is only around 1.5 mPa∙s and 2 mPa∙s at 20°C, respectively 
[46]. Thus, already at room temperature, diffusion and self-interaction of protein molecules will be 
markedly reduced. At -15°C the viscosity is approx. 100 times higher with approx. 400 Pa∙s. Due to 
limitations of the instrument we could not determine the viscosity of the FCs below -15°C. But based 
on the Angell’s Plot [47], Suc FC viscosity can be extrapolated and we obtained values of 703, 1355, 
and 2612 Pa∙s at -20°C, -25°C, and -30°C, respectively. Thus, at product temperatures used during 
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freeze drying for annealing, e.g. -20°C, the viscosity in a FC is around 5 ∙ 105 times higher compared to 
the initial 7% sucrose solution at room temperature which can drastically reduce colloidal interaction 
and unfolding times [48]. 
 
 
Figure 4-2: (A) Viscosity of pure sucrose and sucrose with 0.2 mAb FC (black squares: theoretical values of Suc FC 
obtained based on the Angell’s plot [45] and (B) Diffusion coefficient of mAb in sucrose with 0.2 mAb FC as a 
function of temperature. 
 
We attempted to measure the self-interaction propensity at high sucrose concentrations. Methods 
such as DLS and small-angle X-ray scattering (SAXS) did not work for FCs as the high sucrose 
concentrations interfered with the protein signal in case of DLS and missing contrasts did lead to 
inconclusive results for SAXS. Therefore, CG-MALS was performed for A2 analysis in presence of up to 
5% sucrose and DLS for comparative analysis of A2* in sugar free solutions.  
A2* of mAb in His pH 5.3 resulted in a negative value indicating net attractive self-interaction of the 
mAb (Table 4-3) [49]. Changing the buffer system to Phos pH 7.4 did not substantially modify this 
behaviour. Furthermore, adding NaCl and increasing the ionic strength of these formulations did not 
affect with the self-interactions by changing A2*. At the pH values relatively close to the pI of the mAb 
of between 6 and 7 for different charge species attraction was slightly more dominant with little 
impact of pH and ionic strength [10]. An increased buffer and NaCl concentrations by a factor of 10, 
reflecting the buffer and salt concentration of the FC, resulted in less negative A2* values for all 















15 mM His pH 5.3 -9.37∙10-5 150 mM mM His pH 5.3 -2.05∙10-5 
15 mM His pH 5.3, 20 mM NaCl -9.03∙10-5 150 mM His pH 5.3, 200 mM NaCl -9.71∙10-6 
15 mM Phos pH 7.4 -6.45∙10-5 150 mM Phos pH 7.4 -2.21∙10-6 
15 mM Phos pH 7.4, 20 mM NaCl -3.36∙10-5 150 mM Phos pH 7.4, 200 mM NaCl -2.94∙10-6 
 
Sucrose containing formulations resulted in multimodal size distributions in DLS, which do not allow 
determination of A2*. Therefore, A2 was determined by CG-MALS for a 10 mg/ml mAb solution in 
15 mM His pH 5.3 (Figure 4-3). The A2 value obtained by CG-MALS of the mAb in His pH 5.3 without 
sucrose was comparable with the one determined by DLS. With the addition of sucrose, A2 increased. 
At 2% sucrose positive values resulted, indicating repulsive interaction and qualifying sucrose as 
protein stabiliser [50]. Higher sucrose concentrations are expected to result in even higher repulsive 
forces making the FC favourable for more repulsive protein self-interaction.  
 
 
Figure 4-3: A2 of 10 mg/ml mAb in 15 mM His pH 5.3 at 0 – 5% sucrose obtained by CG-MALS. 
 
To identify the influence of the increased solute content in the FC on the conformational stability, the 
first melting temperature Tm of the mAb and the onset temperature of aggregation Tagg were analysed 
by nanoDSF®. The trend at high temperatures (hot denaturation) is comparable with low temperatures 
(cold denaturation) for various proteins including mAbs [51, 52]. No difference in Tm was found 
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between the different excipients and mAb concentrations in the initial solutions based on 7% sucrose 
(Table 4-4). All Tm values were comparable to the pure mAb in 15 mM His buffer pH 5.3 without 
sucrose. In the NaCl containing formulations and the pH 7.4 formulations except for Phos 7.4 with low 
mAb concentration, aggregation started simultaneously with unfolding. Thus, with the increase in 
hydrophobicity upon unfolding the mAb self-interaction becomes highly attractive. Aggregation did 
not set in with unfolding and was not noticed up to 95°C for pure mAb, Suc, at pH 5.3, and in Suc 
+ Phos 7.4 (0.2% mAb) indicating that despite unfolding repulsive interactions are still dominant under 
these conditions. 
 
Table 4-4: Tm and Tagg of mAb in liquid and freeze concentrated formulations. *not the FC tested, but a 10-fold 
concentrated mAb (2%), comparable to the concentration in the FC. Mean of n = 2. 
 
0.2% mAb 1% mAb 
Initial solution FC Initial solution FC 
Tm [°C] Tagg [°C] Tm [°C] Tagg [°C] Tm [°C] Tagg [°C] Tm [°C] Tagg [°C] 
His 5.3 69.0 >95 68.9* >95* -- -- -- -- 
Suc 69.2 >95 87.6 >110 68.8 >95 86.2 84.6 
Suc + His 5.3 68.0 >95 83.1 80.8 68.4 >95 84.2 82.6 
Suc + His 7.4 68.0 67.1 86.7 84.2 69.1 72.2 86.2 89.0 
Suc + Phos 7.4 66.5 >95 85.8 84.0 68.6 66.7 85.7 >110 
Suc + 0.4 NaCl 69.2 68.8 81.7 80.2 68.3 66.5 80.1 78.5 
Suc + 0.8 NaCl 69.1 68.8 78.3 76.8 68.3 66.7 77.7 76.8 
 
The FCs showed 9°C to 18°C higher Tm and Tagg values compared to the initial solutions [53]. For FCs 
with additional NaCl this difference was less than for the NaCl-free FCs indicating that charge shielding 
by NaCl, i.e. higher ionic strength, led to destabilisation of the protein structure [10]. The mAb 
aggregation behaviour in the FC was similar to that in the initial solution. In the FCs, aggregation of Suc 
0.2% mAb and Suc + Phos 7.4 1% mAb was not completed up to 110°C. The more repulsive interaction 
of the mAb we saw by CG-MALS in presence of sucrose do not have a significant impact when it comes 
to aggregation of the more hydrophobic unfolded mAb. 
Thus, with respect to the physico-chemical properties of the FCs studied, viscosity is enormously 
increased at lower temperatures compared to the initial solution leading to slow reaction rates. 
Thereby, protein interactions are decreased. The presence of a high sucrose concentration in the FCs 






denaturation. NaCl causes more attractive mAb self-interaction and higher susceptibility of unfolding 
and aggregation, but this negative impact of the high solute content in the FC is outweighed by the 
positive impact of sucrose. 
 
3.2 Stability of mAb in FCs 
Subsequently to the characterisation of the FC properties, the aggregation of the mAb in the FC over 
one 1 month was to be analysed in order to learn about protein physical stability itself in the FC liquid 
without ice interface. Thereby, different buffer conditions and the increase in ionic strength through 
NaCl addition were evaluated critically. Initially, the formulations forming the basis of the FCs were 
stressed by freezing and thawing to learn about the short term stability of the mAb in the FC and about 
the impact of the ice interface. Neither visible nor subvisible particles were formed upon three freezing 
and thawing cycles (Figure 4-4).  
 
 
Figure 4-4: Number of subvisible particles ≥ 1 µm/ml of the initial solutions with 7% sucrose containing 0.2% or 
1% mAb before and after 3 freeze-thaw cycles. 
 
 The corresponding FCs were stored for 1 month at 25°C to trigger protein self-interaction, at -10°C 
above Tg’ reflecting collapse and annealing conditions during freeze-drying and at -80°C as reference 
with inhibited mobility below Tg’ and evaluated for mAb aggregation. Tg’ of sucrose is at approximately 
-32°C and 0.2% NaCl in the solution already reduce it by almost 4°C [35, 54, 55]. Overall, the subvisible 
particle concentrations in all FCs was low and no increase was in observed regardless of storage 
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temperature, mAb concentration or buffer system (Figure 4-5). The HMWS levels were at approx. 1% 
to 1.5% after preparation, slightly higher for Suc and Suc + His 5.3 1% mAb. Upon storage, the HMWS 
in the 0.2% mAb FCs did not change at any storage temperature. His 7.4 and both NaCl 1% mAb FCs 
showed an increase in HMWS levels up to 2.5 – 2.7% at all storage temperatures. The fragment levels 
were below 0.5% in all 0.2% FCs and remained consistent over storage. In the 1% mAb FCs the LMWS 
level was increased already at t0 for the pure Suc FC but did not rise further upon storage. Again, His 7.4 
and both NaCl 1% mAb FCs showed signs of additional aggregation to the same extent at all three 
storage temperatures. Thus, we could not see signs of physical instability of the mAb in the FCs based 
on 0.2% initial solution concentration. The FCs based on 1% initial solution concentration and 
containing NaCl showed slight changes in both HMWS and LMWS in SEC, as well as the His 7.4 system, 
independent of storage temperature. The effect in the NaCl may be related to the increased ionic 








Figure 4-5: (A) Subvisible particle, (B) HMWS and (C) LMWS levels of FCs at t0 and after storage at 25°C, -10°C, 
and -80°C for 1 month (t1). 
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The aim of this study was to understand and evaluate protein stability in a maximally freeze 
concentrated solution and the influence of sucrose, buffer, and salt. While protein stability is well at 
temperatures below Tg’ during freeze drying, it could be significantly different above Tg’ during 
annealing or aggressive freeze drying. Furthermore, storage of frozen bulk at temperatures higher Tg’ 
could lack in protein stability. 
All FCs were visibly clear without phase separation or solute solidification at any time. An increase in 
sucrose concentration, which arises during freeze concentration, led to a drastic increase in viscosity 
reducing diffusivity and potentially reducing unfolding. We could not directly analyse the mAb self-
interaction in the FC due to analytical challenges. A2 in our case was less affected by pH and ionic 
strength but increasing the sucrose concentration led to stronger repulsion of the molecules. Tm was 
strongly increased in the freeze-concentrate due to the high sugar concentration. This should mirror 
in improved protein stability against cold denaturation. Tagg was increased according to Tm and both in 
the initial formulation and the FC aggregation occurred immediately with unfolding or was completely 
suppressed. Thus overall, the high sucrose concentration in the FC substantially improves mAb stability 
with respect to self-interaction, aggregation and denaturation. Over 1 month at 25°C, -10°C, and -80°C 
we did not observe visible and subvisible particle formation, and in SEC only in samples with higher 
mAb concentrations a slight HMWS formation was identified. 
Thus, with respect to a lyophilisation process, we conclude no critical impact on mAb quality in the FC 
when the product temperature exceeds Tg’ for a short time during annealing or primary drying. The 
amorphous sugar is an important stabilising factor in this context. These findings are additionally 
important for storage on bulk drug substance. In further studies, different proteins should be analysed 
regarding their stability in the FC, especially at high concentration. 
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Amino acids, for example L-arginine, are used in lyophilisation as crystalline bulking, buffering, viscosity 
reducing or stabilising excipients. In this study, arginine was formulated with different counter ions 
(hydrochloride, citrate, lactobionate, phosphate, and succinate). A monoclonal antibody was 
investigated in sugar-free arginine formulations and mixtures with sucrose regarding cake appearance 
and protein aggregation and fragmentation. Arginine hydrochloride formulations collapsed during 
lyophilisation due to its low Tg’ and partially crystallised during storage, but provided the best protein 
stability at low antibody concentration, followed by arginine succinate. Arginine citrate/ phosphate/ 
lactobionate formulations resulted in amorphous elegant cakes, but inferior protein stability. Addition 
of sucrose improved cake appearance and protein stability. Arginine phosphate with sucrose resulted 
in similar protein stability as the sucrose reference. Mixtures of sucrose with arginine hydrochloride/ 
lactobionate/ succinate provided better stability than sucrose alone. While 50 mg/ml antibody 
improved the cake appearance, only arginine lactobionate provided sufficient protein stability next to 
sucrose. Overall, sugar-free arginine hydrochloride and lactobionate lyophilisates stabilised the 
antibody comparably or better than sucrose depending on antibody concentration. The best protein 
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In order to prolong the shelf life of biopharmaceutics, freeze drying can be used [1]. Sucrose is the 
most frequently utilised excipient due its cryo- and lyoprotecting effect. Its moderate Tg’ of -32°C and 
relatively high Tg of 75°C make sucrose favourable with respect to both process and storage stability 
[2]. Furthermore, isotonic sucrose solutions result in amorphous and elegant cakes [3]. Sucrose is a 
non-reducing sugar, but the glycosidic bond between the two building blocks, glucose and fructose, 
may be broken and the reducing monosaccharides can lead to protein glycation at accelerated or long 
term storage [4]. 
Besides saccharides like sucrose or trehalose, other bulk stabilising excipients are utilised with amino 
acids comprising an interesting group already used in commercially available products [5-8]. A few 
sugar free lyophilisation formulations based on amino acids for biologicals are on the market, e.g. 
ATryn® (antithrombin alfa), with glycine and sodium citrate, Omnitrope® (somatropin), with glycine, 
and Metalyse® (tenecteplase), with arginine and phosphoric acid as main excipients [9]. Various 
lyophilisates comprise both amino acid and sugar, the amino acid in most cases acting as buffer [9]. 
The amino acids differ in their physical and chemical behaviour after freeze drying. L-arginine, 
L-histidine, L-lysine, and L-citrulline form amorphous glasses, whereas glycine, L-phenylalanine, 
L-leucine, and L-isoleucine crystallise [6, 7, 10]. Crystallising amino acids are able to act as scaffolds to 
achieve elegant cake appearance [6, 11]. Nevertheless, proteins lack in stability when freeze dried in 
crystalline excipients only [12-14]. Glass forming amino acids can stabilise proteins by the same 
mechanisms as sugars, i.e. preferential exclusion, water replacement or void filling [5, 15-17]. 
Arginine has received specific attention as it can reduce protein-protein interaction and aggregation in 
liquid formulations and reconstituted lyophilisates [18, 19]. Its stabilising effect derives from a weak 
binding affinity to the protein surface via hydrogen bond formation and ion-dipole interactions [20-
22]. Arginine containing formulations have shown their protein stabilising efficacy in freeze dried 
products depending on the protein, further excipients and concentrations [23]. Arginine in 
combination with further amino acids was able to prevent changes in the secondary structure of anti-
CD11a and anti-IgE antibodies during lyophilisation [24]. A mixture of the three amino acids arginine, 
glutamic acid, and isoleucine was suitable to stabilise b-domain-deleted recombinant FVIII 
(GreenGeneTM F) during production and storage to overcome the need for albumin as stabiliser [25]. 
In a potassium phosphate buffered solution pH 7.0, the addition of at least 2% (w/v) arginine preserved 
the stability of bovine liver catalase during lyophilisation [26]. 




The basic pH of 10.4 of an arginine base solution is not suitable for protein formulation and an acid or 
counter ion is essential for pH adjustment [10]. Furthermore, arginine base shows a very low Tg’ 
of -42.7°C [27]. Different multivalent acids such as phosphoric acid, citric acid, or tartaric acid lead to 
an increase of Tg’ [10]. The counter ion also affects protein stability. After 6 months at 40°C antibody 
formulations containing sucrose and arginine citrate, phosphate or succinate showed more aggregates 
than those with sucrose and arginine hydrochloride  [28, 29]. Schersch et al. showed a protein 
stabilizing effect of arginine phosphate for lyophilisates which collapsed during freeze-drying [30]. 
Although, the stabilising potential of amino acids and especially of arginine containing formulations 
has been shown, a detailed investigation of the stabilising potential of arginine in combination with 
different counter ions and in the absence of additional excipients is still lacking [28, 29]. Therefore, we 
evaluated sugar-free based solely on arginine in combination with hydrochloride, citrate, lactobionate, 
phosphate, and succinate as counter ions and compared them to sucrose-based formulations. The 
formulations were studied with respect to their freeze drying properties, cake characteristics, and 
stabilisation of a monoclonal antibody (mAb) at 2 mg/ml in the pH range between 5.0 and pH 7.0. The 
arginine formulations were also combined with sucrose or high protein concentration of 50 mg/ml to 
evaluate the potential to improve the characteristics of the lyophilised product as well as mAb stability.  
 
2. Materials and Methods 
2.1 Materials 
Stock solutions of sucrose (Merck KGaA, Darmstadt, Germany), L-arginine base (Sigma-Aldrich Chemie 
GmbH, Steinheim Germany), citric acid anhydrous (VWR International, Ismaning, Germany), succinic 
acid (Merck KGaA), and lactobionic acid (Acros Organics, Geel, Belgium) were prepared with highly 
purified water (HPW) or in 15 mM L-histidine buffer (Sigma-Aldrich Chemie GmbH) pH 5.0, 6.0, and 
7.0. In addition, 1 M hydrochloric acid and conc. phosphoric acid (both VWR International) were used. 
The pH of arginine base stock solution was titrated to pH 7.0, 6.0 or 5.0 with citric acid (ArgCitr), 
hydrochloric acid (ArgHCl), lactobionic acid (ArgLacto), phosphoric acid (ArgPhos), and succinic acid 
(ArgSucc). For sucrose formulations (Suc), sucrose was dissolved in the corresponding histidine buffer. 
Arginine formulations containing sucrose were prepared by adding sucrose to the titrated arginine 
formulations at pH 6.0. The following acronyms were used to describe these formulations: SucArgCitr, 
SucArgHCl, SucArgLacto, SucArgPhos, SucArgSucc. Suc based formulations contained 7% (w/w) sucrose 
in 15 mM histidine buffer, Arg based formulations 4% (w/w) arginine and mixed formulations 3.5% 





A monoclonal IgG1 antibody (MW ca. 148 kDa, ϵ = 1.37 mL mg-1 cm-1, referred to as mAb) in 15 mM 
histidine buffer pH 5.3 was used as model protein. Formulations contained 2 mg/ml mAb. Formulations 
with high mAb concentration contained 50 mg/ml mAb and were named ArgHCl-HC, ArgCitr-HC, 
ArgLacto-HC, ArgPhos-HC, ArgSucc-HC, Suc-HC. For HC formulations the mAb was dialysed against 
HPW with a 10-fold buffer exchange in Vivaspin® 20 Ultrafiltration Uni (30 kDa, Sartorius, Goettingen, 
Germany) and up-concentrated. 
The formulations were filtrated with 0.2 µm polyethersulfone membrane syringe filters (VWR 




Freeze-thaw experiments were performed using a FTS LyoStarTM 3 freeze dryer (SP Scientific, Stone 
Ridge, NY, USA). DIN 2R Vials (Fiolax®, Schott AG, Mainz, Germany) were cleaned with highly purified 
water and dried at 60°C for 8 h. The vials were filled with 1.5 mL of sample solution and stoppered with 
lyophilisation stoppers (B2-TR coating, West Pharmaceuticals Services Deutschland GmbH & Co. KG, 
Eschweiler, Germany). Samples were cooled from 20°C to -50°C at a ramp of 1°C/min followed by an 
isothermal hold for 3 h, thawed back to 20°C at a ramp of 1°C/min followed by an isothermal hold of 
3 h. This cycle was repeated three times. Thermocouples in selected vials confirmed complete ice 
crystallisation and thawing and that -50°C and 20 °C resp. were reached in the samples. 
 
2.2.2 Lyophilisation 
Lyophilisation stoppers (B2-TR coating, West) and DIN 2R Vials (Fiolax®, Schott) were cleaned with 
highly purified water and dried at 60°C for 8 h. The vials were filled with 1.5 mL and semi-stoppered 
subsequently. The two outer rows of vials in each batch were not used for analysis. The product 
temperature in different vials at different position over the whole shelf area was record with 
thermocouples. Formulations were freeze-dried according to the protocols shown in Table 5-1 using a 
FTS LyoStarTM 3 freeze dryer (SP Scientific). End of primary drying was controlled by comparative 
pressure measurement between Pirani and MKS sensor. The vials were stoppered after secondary 
drying under nitrogen atmosphere at 800 mbar and crimped with flip-off seals.  




For accelerated stability studies, sucrose reference and sugar free arginine samples pH 5 to 7 were 
stored at 50°C for 6 months, mixtures with sucrose pH 6 and high concentration pH 6 samples were 
stored at 40°C for 6 months. 
 






Pressure [µbar] Hold time [h] 
Cycle 1: Sucrose, ArgCitr, ArgLacto, ArgPhos (pH 5 – 7) 
ArgCitr-HC, ArgHCl-HC, ArgLacto-HC, ArgPhos-HC, ArgSucc-HC, Suc-HC (pH 6) 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 54.5 / 64.7 (HC) 
Secondary Drying 0.4 +40 60 8.3 
Cycle 2: ArgHCl, ArgSucc (pH 5 – 7) 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 40 49.5 
Secondary Drying 0.4 +50 40 5 
Cycle 3: SucArgCitr, SucArgHCl, SucArgLacto, SucArgPhos, SucArgSucc (pH 6) 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 46.5 
Secondary Drying 0.4 +30 60 8.3 
 
2.2.3 Cake appearance 
Images of the lyophilised products were taken with a Nikon D5300 camera (Nikon GmbH, Düsseldorf, 
Germany) in front of a black background. 
 
2.2.4 Differential scanning calorimetry (DSC) 
For the analysis of the glass transition temperature of the maximally freeze-concentrated solution Tg’, 
15 µl sample were filled in aluminium 40 µl crucibles (Mettler Toledo, Gießen, Germany), hermetically 
sealed and analysed with a DSC 821e (Mettler Toledo). The samples were cooled to -60°C at 10 K/min, 
held at -60°C for 5 min and reheated to 20°C at 2 K/min. The Tg’ was determined as the midpoint of 
the phase transition using the STARe software for data analysis. 
The glass transition temperature (Tg) of the lyophilisates was determined with a DSC 821e (Mettler 
Toledo) or a Polyma 314 (Netzsch, Selb, Germany). 5 to 10 mg of crushed cake were filled under 
controlled humidity conditions (less than 10% rel. humidity) into aluminium 40 µl crucibles (Mettler 





ArgHCl were heated to 80°C at 10°/min, cooled to 20°C at 10°/min and reheated to 120°C at 10°/min. 
Other samples were heated to 120°C at 10°/min, cooled to 20°C at 10°/min and reheated to 150°C at 
10°/min. Tg was determined as the midpoint of the phase transition during the second heating using 
the STARe software (Mettler Toledo) or Proteus 7.1 software (Netzsch) for data analysis. 
 
2.2.5 Karl-Fischer titration 
The residual moisture (RM) was analysed by coulometric Karl-Fischer titration using the AQUA 40.00 
titrator with a headspace module (Analytik Jena AG, Halle, Germany). For the measurement about 
20 mg of the lyophilised sample was prepared in a dry atmosphere and heated in the headspace 
module up to 100°C. The evaporated water was transferred into the titration solution and the 
remaining moisture determined. 
 
2.2.6 X-Ray powder diffraction (XRPD) 
The crystallinity of the lyophilised samples was analysed with the X-Ray Diffractometer XRD 3000 TT 
(Rich. Seifert & Co. GmbH & Co. KG, Ahrensberg, Germany), equipped with Cu Kα (40 kV, 30 mA, 
wavelength 154.17 pm). The powders were analysed from 5 – 45° 2°θ with steps of 0.05° 2°θ and 
2 seconds per step. 
 
2.2.7 Reconstitution time 
Reconstitution time was determined by dissolving the lyophilisates with the required volume of HPW. 
The required volume was calculated based on the solid content of each formulation. The time span 
from adding the HPW until complete dissolution was determined visually and considered as 
reconstitution time. During reconstitution, the vials were gently rolled by hand. 
 
2.2.8 Light obscuration 
Light obscuration was used to characterise subvisible particles in the range of 1 to 200 µm. For this 
purpose, a PAMAS SVSS-C35 particle counter with an HCB-LD-25/25 sensor (Partikelmess- und 
Analysensysteme GmbH, Ruthesheim, Germany) was used. Samples were analysed 4 times with 0.2 ml 
each after rinsing the system with 0.2 µm filtrated HPW and a sample pre-rinse with 0.2 ml according 
to USP 788 [31]. At least 3 samples were measured to evaluate the subvisible particle count per ml of 
particles ≥1 µm. 
 





To further assess protein aggregation the turbidity was measured by static light scattering at 90° 
(λ = 860 nm) using a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany). The turbidity was 
recorded in formazine nephelometric units (FNU). 1.5 ml of each sample was analysed in triplicates.  
 
2.2.10 High performance size exclusion chromatography (HP-SEC) 
Size exclusion chromatography was performed with an Agilent 1100 series HPLC system with UV 
detection at 280 nm (Agilent Technologies, Santa Clara, CA, USA). A Waters AQUITY UPLC Protein BEH 
200Å column (1.7 µm; 4.6 x 150 mm; Waters GmbH, Eschborn, Germany) and 50 mM sodium 
phosphate with 400 mM sodium perchlorate buffer at pH 6.0 were used as stationary and mobile 
phase, respectively. The flow rate was set to 0.4 mL/min. Prior to analysis, samples were centrifuged 
(10 min, 7000 rpm, Force7, Denver Instruments, Bohemia, NY, USA). The area of the peaks as well as 
relative areas of monomer, aggregates and fragments were determined after blank subtraction using 
the ChemStation software (Agilent Technologies). 
 
3. Results and Discussion 
3.1 Evaluation of arginine formulations during freeze-thaw cycles 
Already the freezing step during freeze drying can result in a loss in product quality and was therefore 
addressed separately as a first step by characterising the influence of freezing and thawing on mAb 
stability in the presence of arginine and different counter ions [32].  
Freezing and thawing of sucrose reference formulations (pH 6.0) resulted in formation of approx. 
50,000 particles ≥ 1 µm/ml (Figure 5-1). The addition of 0.05% polysorbate 80 to sucrose formulations 
reduced particle formation to less than 10,000 particles ≥ 1 µm/ml. After freezing and thawing, 
ArgPhos pH 5 resulted in the most pronounced particle formation with 1.2 million, followed by ArgCitr 
pH 5 and SucArgCitr with around 100,000, and ArgPhos pH 6 and pH 7 as well as SucArgSucc with 
around 80,000 particles ≥ 1 µm/ml. The other samples were comparable or better than the sucrose 






Figure 5-1. Subvisible particle count after 3 freeze-thaw cycles. 
 
3.2 Protein stability after freeze drying 
Subsequently the stabilising effect of arginine both in pure amino acid based as well as in arginine and 
sucrose containing mAb formulations with different pH and counter-ions was evaluated. The 
formulations were studied with respect to their lyophilisation properties and cake characteristics by 
characterising Tg’ of the frozen liquid as well as Tg, residual moisture, reconstitution times, and cake 
appearance. The colloidal stability of the mAb was assessed by characterising the formation of soluble 
aggregates as well as subvisible particles and turbidity. Chemical degradation of a mAb was assessed 
on the basis of fragmentation. 
 
3.2.1 Tg’ of arginine based formulations 
Pure arginine base has a rather low Tg’ of -42.7°C [27]. The Tg’ of arginine salts strongly depends on the 
counterion and the salt form and does not only reflect the difference in pH value resulting from a 
different amount of acid added. Multivalent acids increase the Tg’ of arginine until a 1:1 mixture is 
reached, whereas monovalent acids tend to decrease Tg’. For example, citric acid brings the Tg’ up to 
around -25°C, whereas acetic acid shows a continuous decrease in Tg’ to values below -50°C [10, 23, 
33]. Too low Tg’ values can cause issues during conventional freeze drying causing poor cake 
appearance due to collapse [34].  
As shown in Table 5-2, ArgHCl and ArgSucc exhibited Tg’ values of approx. -46.5°C and -38.0 °C, 
respectively, which was not affected by pH and was below the Tg’ of sucrose of approx. -32.5 °C. The 




other sugar free arginine formulations ArgCitr and ArgLacto showed substantially higher Tg’ values. 
ArgPhos exhibited a pH dependence of Tg’ with -30.6°C at pH 5 and -27.3°C at pH 7. As the strong pH 
dependent shift of Tg’ was only seen for phosphoric acid but not for the other trivalent acid, citric acid, 
a correlation with nearing one of the pKa values of phosphoric acid cannot be concluded. Furthermore, 
a dependency of Tg’ with respect to different acids in combination with arginine or with increasing 
phosphoric acid concentration were reported without a correlation to the pKa [10, 33]. Addition of 
sucrose led to a shift towards the Tg’ of pure sucrose. The Tg’ for SucArgCitr, SucArgLacto, and 
SucArgPhos became decreased by approx. 3°C and we observed an increase for ArgHCl and ArgSucc by 
8 and 5 °C respectively. This shift can be explained by the Gordon-Taylor equation, which states a mixed 
Tg’ consisting of the mass fraction and the Tg’ values of the individual components [35]. Nevertheless, 
the bell-shaped transition temperature profiles of arginine with organic acids is not explainable by 
Gordon-Taylor [10]. Interestingly, Tg’ of ArgLacto was higher if compared to the pure arginine Tg’, 
although lactobionic acid belongs to the monovalent acids [33]. Tg’ of a pure lactobionic acid solution 
was -30.2 ± 0.3°C leading to a mixed Tg’ explainable by the Gordon-Taylor equation [10]. Increasing the 
mAb concentration from 2 mg/ml to 50 mg/ml mAb led to an increase of Tg’ [34, 36]. Suc-HC exhibited 
an increase of about 2°C, whereas the Tg’ values for ArgHCl-HC and ArgSucc-HC was increased by 
almost 15 °C. 
 
Table 5-2: Tg’ values of sucrose and arginine formulations with mAb. 
Formulation 
Tg’ [°C] 
pH 5 pH 6 pH 7 with sucrose (pH 6) high conc (pH 6) 
Suc -32.5 ± 0.3 -33.5 ± 0.3 -31.3 ± 0.6 -- -31.6 ± 0.4 
ArgCitr -26.4 ± 0.1 -27.1 ± 0.1 -27.2 ± 0.03 -30.4 ± 0.03 -23.1 ± 0.1 
ArgHCl -46.4 ± 0.1 -46.3 ± 0.2 -46.4 ± 0.1 -38.2 ± 0.1 -32.5 ± 0.3 
ArgLacto -26.2 ± 0.3 -25.6 ± 0.05 -25.2 ± 0.4 -28.8 ± 0.2 -21.4 ± 0.1 
ArgPhos -30.6 ± 0.01 -28.7 ± 0.3 -27.3 ± 0.1 -32.1 ± 0.2 -23.8 ± 0.03 
ArgSucc -37.7 ± 0.1 -38.0 ± 0.1 -37.9 ± 0.1 -33.8 ± 0.3 -23.6 ± 0.02 
 
Thus, most of the arginine formulations can be handled by a standard conventional lyophilisation 
process and are expected to result in pharmaceutically acceptable cakes. ArgHCl and ArgSucc must be 







3.2.2 Powder characteristics of the lyophilisates 
Subsequently, sucrose and arginine formulations pH 5 to 7 were freeze dried according to cycle 1. 
ArgCitr, ArgLacto, and ArgPhos resulted in pharmaceutically elegant cakes (Figure 5-3). The pure 
sucrose lyophilisates showed some defects. The pH value did not affect the macroscopic appearance. 
ArgHCl and ArgSucc were substantially collapsed and shrunken since the product temperature of -32°C 
during primary drying in cycle 1 was significantly above Tg’ (Figure 5-2). Less defects could be observed 
when lyophilised at a lower pressure according to cycle 2 resulting in a product temperature of -34°C 
during primary drying (Figure 5-3). Secondary drying temperature was decreased to 30°C for freeze 
drying the mixed arginine sucrose formulations according to cycle 3 (Figure 5-3). The addition of 
sucrose did not influence cake appearance of ArgCitr, ArgLacto, and ArgPhos based lyophilisates and 
improved the appearance of ArgHCl and ArgSucc based cakes. 50 mg/ml mAb formulations freeze 
dried according to cycle 1 resulting in a product temperature of -36°C during primary drying were all 
elegant products due to the higher Tg’ values and the increased total solid contents. Cake appearance 
of all the formulations did not change over 6 months storage at 40°C or 50°C.  
 
 
Figure 5-2. Macroscopic appearance of ArgHCl and ArgSucc at pH 6 lyophilized according to cycle 1. 
 





Figure 5-3. Macroscopic appearance of sucrose and arginine lyophilisates pH 5.0, 6.0, and 7.0 that differ in the 
counter ion, the addition of sucrose, and mAb content. Freeze drying cycle 1 was used for Suc, ArgCitr, ArgLacto, 
and ArgPhos without sucrose, as well as all 50 mg/ml mAb lyophilisates; cycle 2 was used for ArgHCl and ArgSucc 
without sucrose; cycle 3 was used for all arginine-sucrose mixtures. The symbol + represents good cake 
appearance, o minor cake shrinkage/minor structural defects, and – major cake shrinkage/structural defects. 
 
Overall, ArgHCl and ArgSucc required low product temperatures during primary drying to gain elegant 
cakes. A mixture with sucrose or the addition of a high mAb concentration can improve slow primary 
drying times due to their low Tg’ values and resulted in acceptable cakes. Other arginine formulations 
showed elegant cakes after freeze drying in a standard procedure. 
The sucrose reference showed a Tg value of 65°C and a RM of 0.5% after lyophilisation [37]. Tg did not 
significantly change upon storage at 50°C for up to 6 months while RM increased slightly to 0.9% 
(Figure 5-4). Overall, the Arg based lyophilisates showed very high Tg and low RM values after 
production. Similar to Tg’, the Tg of freeze dried arginine with multivalent counter ions increased with 
increasing pH [33], whereas ArgHCl and ArgLacto lyophilisates were not affected by pH. ArgCitr showed 
the highest Tg values of 90°C to 120°C (RM of 0.3%), followed by ArgPhos and ArgSucc. ArgHCl and 
ArgLacto lyophilisates had similar Tg values of 80°C independent of pH. After 6 months storage at 50°C, 





decreased by up to 15°C [19, 38]. Even after storage, Tg was above storage temperature indicating 
potential protein stability through immobilisation in the amorphous matrix [39, 40]. 
 
 
Figure 5-4. Tg (A) and RM (B) of sucrose and arginine based 2 mg/ml mAb lyophilisates at pH 5, 6 and 7 (5, 6, 7) 
stored at 50°C, as a mix with sucrose at pH 6 (S) and at pH 6 with 50 mg/ml mAb (HC) after lyophilisation (t0) and 
upon storage at 40°C for 1 (t1), 3 (t3) and 6 months (t6). 
 
Mixtures of sucrose and arginine salts were freeze dried according to cycle 3 with a lower secondary 
drying temperature resulting in higher RM levels after production except for ArgLacto. The higher RM 
levels and the addition of sucrose led to a decrease in Tg to 55°C for SucArgHCl and between 72°C and 
slightly above 80°C for SucArgCitr, SucArgPhos, SucArgSucc and SucArgLacto. During 6 months storage 
at 40°C, the Tg slightly decreased by approx. 5°C.  




Products with 50 mg/ml mAb resulted in similar RM and the higher protein concentrations led to even 
further increased Tg values [41]. An increase by 10°C up to 20°C was found for ArgPhos-HC, ArgLacto-
HC, and Suc-HC, a drastic increase by 40°C for ArgSucc-HC. Hardly any change was found for ArgCitr-
HC, which already exhibited an extremely high Tg, and ArgHCl-HC, which was unexpected as an increase 
was identified in literature [28]. 
Sugar-free Arg based formulations exhibited extremely high Tg values compared to the sucrose 
reference formulation pointing towards high protein stability in the immobilised amorphous phase [39, 
40]. In combination with sucrose, Tg values were decreased slightly according to a mixed Tg based on 
the Gordon-Taylor equation [10] but the values are still high overall. 
All samples showed a Tg in DSC analysis and were fully amorphous according to XRPD except for ArgHCl 
stored for 3 or 6 months, independent of pH (Figure 5-5). The addition of sucrose as well as a high mAb 








Figure 5-5. XRPD of (A) 2 mg/ml mAb pH 6 samples after 6 months storage at 50°C, (B) mixtures of arginine and 
sucrose pH 6 samples after 6 months storage at 40°C, (C) 50 mg/ml mAb pH 6 samples after 6 months storage at 
40°C, and (D) ArgHCl pH 5, 6, and 7 after 3 months storage at 50°C. 
 
Reconstitution of all 2 mg/ml mAb samples was completed within 30 s at t0 and after storage. The 
50 mg/ml mAb samples based on ArgHCl showed the same fast reconstitution. For all other 
formulations, reconstitution took longer with up to 60 s for ArgCitr-HC, ArgLacto-HC, and ArgSucc-HC 
and 3 min for ArgPhos-HC, which increased further upon storage. Thus, arginine based lyophilisates 
dissolve which makes especially ArgHCl a promising alternative candidate for highly concentrated mAb 
sugar based lyophilisates with delayed dissolution times [6, 42]. 
 
 




3.2.3 mAb stability during lyophilisation and upon storage 
The mAb process and storage stability was analysed with respect to aggregation by SEC, turbidity and 
subvisible particle analysis by light obscuration in order to assess colloidal stability of the mAb. 
Furthermore, information on fragmentation was collected via the SEC measurements in order to 
evaluate chemical stability of the formulations.  
The sucrose reference formulations pH 5, 6, and 7 resulted in low particle counts after lyophilisation 
with less than 30,000 particles ≥ 1 µm/ml and a turbidity of < 5 FNU (Table 5-3). Less than 2% HMWS 
were found for all pH values (Figure 5-6). After 6 months storage at 50°C, particle count and turbidity 
increased in a pH dependent manner. While pH 5 revealed no changes, pH 7 resulted in around 
90,000 particles and 11.7 FNU turbidity. Additionally, large and rapidly sedimenting visible particles 
had formed. The HMWS level did not increase but the relative monomer recovery compared to t0 







Table 5-3: Subvisible particle count and turbidity data of sucrose and arginine based 2 mg/ml mAb lyophilisates 
at pH 5, 6, and 7 (5, 6, 7) stored at 50°C, as a mix of sucrose at pH 6 (S) stored at 40°C, and at pH 6 with 50 mg/ml 
mAb (HC) after lyophilisation (t0) and after 6 months storage (t6) at 40°C. Turbidity data marked with * were 
analysed after 3 months storage. 
 Subvisible particle count ≥ 1 µm/ml Turbidity [FNU] 





 5 23,425  ± 947 8,003  ± 1,257 3.3  ± 0.4 3.1 ± 0.1 
6 24,623  ± 2,334 53,550  ± 7,280 3.3  ± 0.8 7.7 ± 0.3 
7 28,520  ± 2,926 90,296  ± 17,487 4.6  ± 1.5 11.7 ± 1.0 






S 31,045  ± 9,252 42,826  ± 9,904 2.7  ± 0.5 6.4 ± 0.8 
5 60,562  ± 18,570 118,557  ± 22,679 4.9  ± 3.6 12.9 ± 0.7 
6 15,705  ± 3,704 144,738  ± 25,431 2.8  ± 0.7 11.5 ± 1.7 
7 14,450  ± 1,439 144,651  ± 24,362 4.6  + 2.2 11.9 ± 0.4 






S 10,559  ± 1,281 12,726  ± 3,208 2.6  ± 0.4 4.8 ± 1.0 
5 4,638  ± 716 23,947  ± 7,182 3.4  ± 1.1 4.2 ± 0.5 
6 1,311  ± 475 41,502  ± 4,358 2.4  ± 0.1 5.6 ± 0.3 
7 1,685  ± 229 74,419  ± 10,053 3.4  ± 1.1 7.1 ± 0.02 






 S 23,017  ± 5,325 54,532  ± 10,957 3.1  ± 0.3 7.0 ± 0.2 
5 58,353  ± 26,010 101,698  ± 32,743 5.7  ± 1.1 14.5 ± 1.2 
6 56,680  ± 13,404 113,148  ± 36,471 6.7  ± 1.3 16.9 ± 0.7 
7 42,961  ± 12,292 122,398  ± 40,258 3.9  ± 0.7 18.3 ± 0.7 







S 13,315  ± 3,783 29,408  ± 4,107 2.6  ± 0.4 5.9 ± 0.1 
5 53,938  ± 12,009 144,320  ± 16,079 6.0  ± 1.2 17.0 ± 1.1 
6 30,348  ± 5,273 135,814  ± 20,690 3.9  ± 0.5 13.1 ± 1.1 
7 46,976  ± 5,529 116,887  ± 17,356 5.6  ± 0.7 11.7 ± 0.2 






S 14,294  ± 2,929 33,445  ± 4,962 2.5  ± 0.3 7.9 ± 1.1 
5 16,852  ± 3,368 48,648  ± 9,856 4.2  ± 0.2 5.8 ± 0.4 
6 9,692  ± 1,903 112,868  ± 18,386 2.8  ± 0.5 8.1 ± 3.6 
7 9,238  ± 2,327 116,937  ± 18,206 2.8  ± 0.6 16.3 ± 1.0 
HC 15,966  ± 2,923 73,258  ± 23,688 12.2  ± 0.3 13.9 ± 0.9* 
 





Figure 5-6. (A) Higher molecular weight species (HMWS), (B) lower molecular weight species (LMWS), and (C) 
relative monomer recovery of sucrose and arginine based 2 mg/ml mAb lyophilisates at pH 5, 6 and 7 (5, 6, 7), as 
a mix with sucrose at pH 6 (S) and at pH 6 with 50 mg/ml mAb (HC) after lyophilisation (t0) and upon storage for 





The sugar-free arginine based 2 mg/ml mAb products differed depending on counter ion and pH. 
Whereas the number of particles ≥ 1 µm/ml was similar or slightly higher for ArgCitr, ArgLacto and 
ArgPhos, the mAb showed substantially better process stability in ArgHCl and ArgSucc with less 
than 5,000 and < 17,000 particles, respectively. Turbidity and HMWS content were similar for all 
formulations and comparable to sucrose. 
After 6 months storage at 50°C, the particle count of ArgCitr, ArgLacto, and ArgPhos was higher than 
100,000 and turbidity reached values above 10 FNU. These formulations showed a slight pH 
dependency. ArgCitr and ArgLacto showed an increase in particle count with increasing pH, moving 
closer to the IEP of the mAb of around 8.0. This tendency is less pronounced for ArgPhos, which 
correspond to the freeze/thaw experiments where higher particle formation only occurred at pH 5. 
Overall similar trends were observed in HMWS content and relative monomer recovery. The HMWS 
content increased up to 4% in ArgLacto and up to 10% and 14% at pH 7 for ArgCitr and ArgPhos 
respectively. The relative monomer recovery decreased to 85% in ArgLacto, 80% in ArgCitr, and 
75 – 82% in ArgPhos. The mAb stability after 6 months at 40°C in ArgSucc lyophilisates was superior at 
pH 5 with less than 50,000 particles ≥ 1 µm/ml, turbidity below 10 FNU, approx. 3% HMWS and more 
than 97% monomer recovery. At pH pH 6 and 7 the particle numbers were higher. ArgHCl formulations 
exhibited the best stability with the lowest particle numbers, turbidity values below 10 FNU, no 
increase in HMWS level and no monomer loss in SEC. 
In general, mixtures of sucrose and arginine at pH 6 showed a better process stability. Only for 
SucArgHCl a slightly higher particle count compared to pure ArgHCl product was seen. After 6 months 
storage at 40°C, all formulations resulted in a less pronounced increase in particle count compared to 
the sugar free formulations. Most particles were found for SucArgLacto with around 55,000 particles, 
which was comparable to pure sucrose. The turbidity was similar or lower compared to both pure 
sucrose and the sugar-free products. The HMWS levels increased and the relative monomer recovery 
decreased in none of the formulations. Only a slight increase in HMWS formation from 2.9% to max. 
4.1% upon storage at 40°C was observed in literature for sucrose mixtures with 50 mg/ml mAb [29]. 
Increasing the mAb concentration to 50 mg/ml resulted in similar of slightly lower particle levels. The 
turbidity values were significant higher with around 10 FNU compared to 2 mg/ml products, except for 
ArgHCl-HC which was low with 4.2 FNU. Aggregate levels of around 3% HMWS were found. After 
6 months storage at 40°C, particle counts increased less compared to the corresponding 2 mg/ml 
samples. Again, ArgCitr-HC, ArgPhos-HC, and ArgSucc-HC were comparable to the sucrose reference 
Suc-HC reference and ArgLacto-HC and ArgHCl-HC were superior. The turbidity increased slightly in all 
formulations and the HMWS levels in Suc-HC and ArgLacto-HC went up to 4% and to 7 – 10% in all 




other arginine formulations including ArgHCl-HC. A decrease in relative monomer recovery was not 
observed. Thus, at high mAb concentration ArgHCl and ArgLacto were beneficial with ArgHCl forming 
the least amount of larger aggregates and ArgLacto the least soluble aggregates. 
All formulations showed comparable stability against cleavage. Overall, the mAb did not undergo 
severe fragmentation in any formulation upon freeze drying and storage (Figure 5-6B). 
Thus, despite providing the lowest Tg of all tested counter ions, the monovalent hydrochloric acid was 
the most suitable counter ion for arginine to stabilise the mAb during freeze-drying and storage, 
independent of the pH value and addition of sucrose. Overall it provided better protein stability 
compared to the sucrose reference formulations. This is in good agreement with previously published 
data similarly concluding best protein stability for ArgHCl lyophilisates [29]. Multivalent counter ions 
resulted in reduced protein stability compared to ArgHCl, with the counter ion succinic acid being an 
exception at pH 5. The amorphous matrices of arginine with multivalent counter ions are different to 
ArgHCl matrices, indicated by high Tg values of up to 120°C. Accordingly, they seem to act differently 
in terms of stabilising a mAb. The use of arginine lyophilisates in marketed products further supports 
the potential of sugar-free arginine formulations [9]. 
The addition of sucrose to arginine formulations resulted in good or better results for particle 
formation and protein stability compared to the sucrose reference, again similar to previous reports 
[28, 29]. A high mAb concentration of 50 mg/ml resulted in overall low particle counts and ArgLacto-HC 
turned out to be an interesting formulation candidate next to ArgHCl-HC. 
 
4. Conclusion 
The aim of this study was to test sugar-free arginine based formulations as alternatives to sucrose or 
sucrose-containing arginine formulations for lyophilisation of biopharmaceuticals. By using a sugar-
free formulation approach, potential glycation issues, which may occur in sucrose based formulations, 
can be circumvented in an elegant way [2, 4]. We studied the freeze-drying performance of sugar-free 
arginine formulations with different counterions at different pH with 2 and 50 mg/ml of an exemplary 
mAb. The freeze-thaw stability of the mAb as well as the physicochemical characteristics and the mAb 
stability during freeze-drying and upon subsequent storage up to 6 months at 40°C or 50°C were 
studied. The sucrose references pH 5 to pH 7 showed good cake appearance and remained amorphous 
over storage. They were characterised by a Tg of 65°C [37]. The lyophilisates exhibited low particle 
counts and did not show an increase in HMWS but substantial subvisible and visible particle formation, 





Stability of the antibody upon freezing and thawing in ArgHCl, ArgLacto or ArgSucc formations were 
found to be comparable or better than in a sucrose formulation. Potential protein instabilities during 
the freezing step of the applied freeze-drying process for arginine formulations could be excluded for 
these formulations. 
Tg’ was increased compared to the sucrose formulation by using arginine in combination with citric, 
lactobionic, and phosphoric acid potentially enabling a more robust and faster lyophilisation process. 
The Tg’ values of ArgHCl and ArgSucc at 2 mg/ml mAb were very low with -46°C and -38°C, respectively, 
which poses challenges in the opposite way. This challenge can be overcome by adding sucrose or 
using high mAb concentration leading to an increase in Tg’. By running an adapted freeze drying cycle 
for ArgHCl and ArgSucc, all formulations resulted in good cake appearance which did not change over 
storage. The Tg values of ArgHCl and sucrose lyophilisates were similar with approx. 65°C whereas the 
other arginine formulations showed even higher Tg values of up to 120°C. All formulations exhibited Tg 
values well above the intended storage temperature providing a good forecast for protein stabilisation 
through protein immobilisation in the amorphous matrix [39, 40]. ArgHCl partially crystallised after 
3 months at 50°C but crystallisation was suppressed in the sucrose mixtures or at 50 mg/ml mAb at 
40°C storage temperature. The Arg based lyophilisates reconstituted fast. At 50 mg/ml mAb, 
reconstitution times were prolonged except for ArgHCl-HC taking only 30 sec for complete dissolution, 
which could be highly valuable asset for high concentration formulation or large fill volumes [42]. Both 
process and storage stability of the mAb was superior in ArgHCl and ArgSucc if compared to sucrose 
with respect to aggregation. Mixtures of arginine and sucrose improved both process and storage 
stability of the mAb compared to a sucrose formulation without arginine. At high mAb concentration 
ArgHCl-HC and ArgLacto-HC provided good process and storage stability with respect to aggregation 
and fragmentation. 
In summary, this study presented sugar-free Arg based formulations as potential alternative to sucrose 
or sucrose-containing arginine lyophilisates for biopharmaceuticals, which were already reported in 
literature [28, 29]. While multivalent acids as counter ions enhance Tg’ and Tg to values above 
corresponding sucrose formulations and provide good process characteristics, they showed a lack in 
protein stabilisation. Arginine formulations in combination with the counter ions succinate and 
lactobionate were comparable in both cake appearance and protein stabilisation efficiency to the 
sucrose reference formulation. The monovalent hydrochloride rendered outstanding protein stability. 
The low Tg’ values of ArgSucc and ArgHCl with low mAb concentration may pose challenges in freeze 
drying and corrupt the cake appearance but this can be overcome by addition of sucrose and 
potentially other crystalline bulking agents. Further studies should address these drawbacks while 




maintaining protein stability. Overall, arginine based lyophilisates do have both advantages and 
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Amino acids are not only used as buffering agents in lyophilisation, but also exhibit cryo- and 
lyoprotecting characteristics. L-Arginine based lyophilisates were tested regarding their ability to 
stabilise a monoclonal antibody (mAb) at different residual moisture (RM) levels. Arginine base was 
formulated with citric, hydrochloric, lactobionic, phosphoric, and succinic acid for pH adjustment. 
Lyophilisates with less than 0.5% and approx. 2.5% RM were stored for up to 6 months at 40°C. The 
mAb aggregation in arginine in combination with hydrochloric acid and succinic acid was similar or 
even less compared to a sucrose reference formulation. Arginine in combination with citric acid, 
lactobionic acid, and phosphoric acid resulted in lower protein stability. Overall, arginine formulations 
with high RM levels resulted in better protein stabilisation despite decreased glass transition 
temperatures (Tg). Whereas we detected mAb glycation in the sucrose based formulations, this 
chemical reaction did not occur in arginine based formulations. Arginine hydrochloride and succinate, 
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Lyophilisation of is frequently used to improve the long-term storage stability of protein 
pharmaceuticals. Protein stability is typically attributed to the reduced mobility in the glassy 
amorphous matrix [1]. Stabilisation has also been ascribed to replacement of water molecules by sugar 
molecules, which can form hydrogen bonds with the protein [2, 3]. This raises the question whether 
all water molecules stabilising the native state of the protein can be replaced or how many water 
molecules should remain to grant optimal protein stability. It is commonly stated that products should 
be freeze dried below 1% residual moisture (RM) [1, 4-6]. An enhanced loss of protein activity may 
occur with overdried samples and chemical and physical instability may be more pronounced at higher 
RM of 3 – 10% [7-9]. Overall, individual formulations have to be freeze dried to their optimal RM area 
also keeping in mind that product specifications have to be set based on a rational. 
Only a few sugar free lyophilisates for biopharmaceuticals based on amino acids are available on the 
market, e.g. Metalyse® (tenecteplase) with arginine and phosphoric acid as main excipients [10]. 
Arginine has the ability to reduce protein aggregation in liquid and after reconstitution, which makes 
arginine salts of special interest for formulation development [11-13]. The protein stabilising effect of 
arginine containing lyophilisates is dependent on the protein, other excipients, and the concentrations 
used [14, 15]. Since the pure base has a pH of 10.4 counter ions are necessary for pH adjustment [16, 
17]. Furthermore, the glass forming ability depends on the counter ion [16, 18, 19]. Exceptionally high 
glass transition temperatures (Tg) have been described for arginine with multivalent anions like 
phosphate and citrate, whereas markedly lower Tg values result for monovalent anions like 
hydrochloride [16, 20, 21]. The low Tg of the arginine and hydrochloride combination is related to a 
low Tg’ of -42.5°C which may lead to macro- or microcollapse, eventually resulting in higher RM levels 
[20]. 
So far, the effect of RM on the protein stability in sugar-free arginine based lyophilisates has not been 
addressed in research. A slight increase in RM during storage in sucrose formulations can cause a 
strong decrease in Tg [7]. An increase in RM in arginine formulations with an extremely high Tg might 
result in sufficiently high Tg values, also over storage, to maintain protein stability. 
We analysed mAb aggregation in arginine salt (citrate, hydrochloride, lactobionate, phosphate, 
succinate) lyophilisates at two different RM levels. Formulations were tested at less than 0.5% RM to 
simulate overdrying and approx. 2.5% RM as high moisture level. Over 6 months storage at 40°C less 
mAb aggregation occurred at high compared to low RM levels of all arginine formulations. The protein 
stability in arginine succinate was similar to that in the sucrose reference formulation. High RM 
arginine hydrochloride cakes collapsed due to their lower Tg over storage, but they did not show 




particle or HMWS formation providing superior stability over sucrose. The sucrose reference 
formulation provided markedly less protein stabilization at high RM and additionally glycation 
occurred. Glycation was further assessed in sucrose containing formulations (sucrose and 
mannitol:sucrose 4:1) over 9 months at 60°C and compared to arginine citrate and hydrochloride 
lyophilisates.  
 
2. Materials and Methods 
2.1 Materials 
Sucrose and succinic acid (Merck KGaA, Darmstadt, Germany), L-arginine base, L-histidine base, 
L-histidine hydrochloride monohydrate, and D-Mannitol (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany), citric acid anhydrous, di-sodiumhydrogen phosphate dihydrate, and sodiumdihydrogen 
phosphate dihydrate (VWR International, Ismaning, Germany), and lactobionic acid (Acros Organics, 
Geel, Belgium), 1 M hydrochloric acid (VWR International), and conc. phosphoric acid (VWR 
International) were used to prepare stock solutions in highly purified water (HPW, Arium Pro, Sartorius, 
Göttingen, Germany).  
Sucrose stock solution and formulation (Suc) were prepared in 15 mM histidine buffer pH 6.0. After 
dilution with buffer, Suc contained 7% (w/w) sucrose in 15 mM histidine buffer pH 6.0. Arginine base 
stock solution was titrated with the acid solution until pH 6.0 was reached. The following acronyms 
were used for the arginine formulations: ArgCitr, ArgHCl, ArgLacto, ArgPhos, ArgSucc. The final arginine 
formulations contained 4% (w/w) arginine in HPW.  
For the glycation study, a ratio of 4:1 mannitol to sucrose (Man:Suc) and Suc stock solutions in 15 mM 
phosphate buffer pH 7.2 were used. ArgCitrglyc and ArgHClglyc were titrated to pH 7.2 as described 
above. After dilution with phosphate buffer, Sucglyc and Man:Suc contained 7% (w/w) sucrose or 
mannitol:sucrose 4:1, respectively, in 15 mM phosphate buffer pH 7.2 and ArgCitrglyc and ArgHClglyc 
contained 4% (w/w) arginine in HPW. 
A monoclonal IgG1 antibody (MW ca. 148 kDa, ϵ = 1.37 mL mg-1 cm-1; mAb) was used at 2 mg/ml as 
model protein. 









Prior to use, lyophilisation stoppers (B2-TR coating, West Pharmaceuticals Services Deutschland GmbH 
& Co. KG, Eschweiler, Germany) and DIN 2R Vials (Fiolax®, Schott AG, Mainz, Germany) were cleaned 
with HPW and dried at 60°C for 8 h. The vials were filled with 1.5 mL formulation and semi-stoppered. 
Both placebo and protein formulations were freeze-dried according the protocols in Table 6-1 using a 
FTS LyostarTM 3 freeze dryer (SP Scientific, Stone Ridge, NY, USA). Thermocouples, placed in different 
vials positioned over the shelf, were used for temperature recording. Comparative pressure 
measurement between Pirani and MKS sensor was used for the end of primary drying detection. The 
vials were stoppered at 800 mbar after secondary drying and crimped with flip-off seals. 
Samples were analysed after lyophilisation and after 1, 3, and 6 months storage at 40°C. 
 
Table 6-1: Freeze drying protocols. 
Step Ramp [°C/min] 
Shelf 
temperature [°C] 
Pressure [µbar] Hold time [h] 
Cycle 1: High residual moisture 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 48 
Secondary Drying 0.4 20 60 5 
Cycle 2: Low residual moisture 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 48 
Secondary Drying 0.4 40 60 12 
Cycle 3: Glycation samples - high residual moisture 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 48 
Secondary Drying 0.4 20 60 5 
Cycle 4: Glycation samples - low residual moisture 
Freezing 1.0 -50 - 1.5 
Primary Drying 0.5 -20 60 48 













2.2.2 Cake appearance 
To visualise the cake appearance, images of the lyophilised products were taken in front of a black 
background with a Nikon D5300 camera (Nikon GmbH, Düsseldorf, Germany). 
 
2.2.3 Differential scanning calorimetry (DSC) 
The glass transition temperature (Tg) of the lyophilised products was determined with a DSC 821e 
(Mettler Toledo, Gießen, Germany). Up to 10 mg crushed cake were filled at < 10% r.h. conditions into 
40 µl aluminium crucibles and hermetically sealed. Samples containing Suc or ArgHCl were heated to 
80°C at 10°C/min, cooled to 10°C at 10°C/min, and reheated to 120°C at 10°C/min. Other samples were 
heated to 120°C at 10°C/min, cooled to 10°C at 10°C/min, and reheated to 150°C at 10°C/min. The 
midpoint of the phase transition in the second heating step was determined as Tg. 
 
2.2.4 Karl-Fischer titration 
Residual moisture (RM) analysis was performed by coulometric Karl-Fischer titration (AQUA 40.00, 
Analytik Jena AG, Halle, Germany) with a headspace module. About 20 mg crushed lyophilised product 
was prepared under dry atmosphere (< 10% rel. humidity) and heated up to 100°C in the headspace 
module. The evaporated water was transferred into the titration solution and RM determined. 
 
2.2.5 X-Ray powder diffraction (XRPD) 
Powder morphology was analysed with an X-Ray Diffractometer XRD 3000 TT (Rich. Seifert & Co. 
GmbH & Co. KG, Ahrensberg, Germany) from 5 – 45° 2θ with steps of 0.05° 2θ and 2 seconds per step 
(Cu Kα, 40 kV, 30 mA, λ = 154.17 pm). 
 
2.2.6 Reconstitution time 
Samples were reconstituted with HPW considering the water mass removed by lyophilisation for each 
formulation. Vials were gently rolled by hand. The time until complete dissolution based on visual 






2.2.7 Light obscuration 
Subvisible particles between 1 and 200 µm were characterised by light obscuration with the PAMAS 
SVSS-C35 particle counter with an HCB-LD-25/25 sensor (Partikelmess- und Analysensysteme GmbH, 
Ruthesheim, Germany). After sample pre-rinse with 0.2 ml, each sample was analysed 4 times with 
0.2 ml according to USP 787 [22]. Between each sample, the system was rinsed with 0.2 µm filtrated 
HPW. At least 3 samples/formulation were used for calculating the subvisible particle count of particles 
≥ 1 µm, ≥ 10 µm, and ≥ 25 µm per ml. 
 
2.2.8 High performance size exclusion chromatography (HP-SEC) 
Higher and lower molecular weight species (HMWS/LMWS) were analysed with size exclusion 
chromatography using an Agilent 1100 series HPLC system, equipped with an UV/Vis detector (280 nm; 
Agilent Technologies, Santa Clara, CA, USA). A Waters AQUITY UPLC Protein BEH 200Å column (1.7 µm, 
4.6 x 150 mm, Waters GmbH, Eschborn, Germany) was used with the following parameters: 50 mM 
sodium phosphate with 400 mM sodium perchlorate buffer pH 6.0 as mobile phase with a flow rate of 
0.4 ml/min. Prior to analysis, samples were centrifuged at 7000 rpm for 10 min (Force7, Denver 
Instruments, Bohemia, NY, USA). The integrated peak area was determined after blank subtraction 
using the ChemStation software (Agilent Technologies) and relative areas were calculated. 
 
2.2.9 Boronate affinity chromatography (BAC) 
Glycation was detected with boronate affinity chromatography by using an Agilent 1200 series HPLC 
system equipped with a UV/Vis detector at 280 nm (Agilent Technologies). A TSK Boronate-5PW 
column (7.5 x 75 mm, Tosoh Bioscience, Stuttgart, Germany) was used with Buffer A (100 mM HEPES, 
200 mM NaCl, 70 mM Tris, pH 8.6) and Buffer B (500 mM sorbitol in Buffer A) [23]. After injection, 
Buffer A was kept at 100% for 10 min followed by a linear gradient of Buffer B from 0% to 100% in 
5 min. Buffer B was kept at 100% for 3 min. Within 1 min, the system was flushed back to Buffer A until 
the end of the run after 35 min. A flow rate of 1 ml/min was used with a column temperature of 40°C. 
The degree of glycation in % was calculated as the ratio of the AUC of the individual curves, integrated 
and blank subtracted with the ChemStation software (Agilent). The first peak at around 2.5 min was 
referred to as non-glycated species and the second peak at around 15.5 min was referred to as glycated 
species. 
 




2.2.10 Circular dichroism (CD) 
Mab containing ArgCitr, ArgHCl, and ArgPhos samples were diluted with formulation buffer to 
0.4 mg/ml for the near-UV circular dichroic measurements (250 – 320 nm). The spectra were collected 
at 25°C with a Jasco J-810 spectropolarimeter (JASCO Deutschland GmbH, Pfungstadt, Germany). 
Quartz cuvettes with 10 mm path length were used at a scan rate of 20 nm/min. The spectrum of the 
respective buffer was subtracted for each sample and the mean residue ellipticity calculated [24]. 
 
3. Results and Discussion 
3.1 Investigation of protein stability in low and high residual moisture 
lyophilisates 
3.1.1 Physical chemical characterisation of lyophilisates with low and high residual moisture 
The major aim of this study was to identify and understand the influence of residual moisture on the 
ability of arginine, depending on its counter ion, to stabilise proteins during and after lyophilisation 
compared to the gold standard sucrose. Therefore, different arginine formulations were lyophilised by 
different secondary drying conditions to obtain different residual moisture levels. 
Arginine containing formulations result in higher RM values compared to the sucrose reference 
formulation with 0.2% to 0.5% RM compared to 0.2% and 2.2% to 3.2% RM compared to 1.5% for high 
and low RM samples (Figure 6-1A and B). This may be related to a difference in water affinity, the 
higher total solid content or microcollapse of the arginine based formulations [15, 20]. Upon storage, 
arginine formulations showed a more pronounced increase in RM compared to the sugar based 
formulation [12, 15, 25]. Interestingly, high RM sucrose had a significantly lower RM level compared 
to the arginine formulations over the whole storage time. Within each set, ArgHCl and ArgSucc 
consistently showed higher RM values compared to ArgCitr, ArgLacto, and ArgPhos, due to collapse 
and shrinkage which opposes water removal during lyophilisation. 
The differences in RM were reflected in Tg (Figure 6-1C and D) [7]. Within the Low RM lyophilisates, 
Suc and ArgHCl showed the lowest Tg values with around 65°C, increasing in the order ArgSucc, 
ArgPhos, ArgLacto, and ArgCitr to 120°C. The same ranking was found for the high RM formulations, 
but with overall lower Tg values. During storage, the Tg values decreased slightly, which corresponds 
to the increase in RM [7]. Nevertheless, Tg values of arginine formulations except for ArgHCl remained 





1 month storage at 40°C for both, high and low RM. All other products remained fully amorphous over 
the entire time. 
 
 
Figure 6-1: RM and Tg results of sucrose and arginine formulations over 6 months at 40°C. A. RM of low RM 
samples. B. RM of high RM samples. C. Tg of low RM samples. D. Tg of high RM samples. Both Suc and ArgHCl with 
high RM collapsed during storage and were not analysed after 6 months. 
 
Right after lyophilisation, samples with both high and low RM showed the same macroscopic 
appearance. Sucrose and ArgSucc were slightly shrunken, whereas ArgHCl had partially collapsed 
(Figure 6-2). ArgHCl is prone for collapse due to its low Tg’ [15, 20, 25]. After 6 months storage at 40°C, 
the formulations with low RM did not change. Within the high RM samples, Suc and ArgHCl showed 
complete collapse and approx. one third of the Suc and Suc placebo vials showed discolouration. 





Figure 6-2: Macroscopic appearance of sucrose and arginine formulations after lyophilisation and after 6 months 
storage at 40°C. 
 
All lyophilisates reconstituted within 30 seconds at t0. The reconstitution time did not change except 
for the fully collapsed ArgHCl and Suc formulations with high RM which required up to 6 min and 






3.1.2 mAb stability with low and high residual moisture during lyophilisation and upon storage 
The effect of residual moisture level on protein aggregation was studied considering formation of 
subvisible particles (Figure 6-3) and HMWS in SEC (Figure 6-4). Sucrose low RM was set as benchmark 
with approx. 25,000 particles ≥ 1 µm/ml, approx. 300 particles ≥ 10µm/ml, and approx. 10 particles 
≥ 25 µm/ml after lyophilisation and over 6 months storage at 40°C. The HMWS level of 2% HMWS after 
lyophilisation did not change over 6 months storage. In contrast, Suc high RM, starting at the 
benchmark level after lyophilisation, showed an enormous increase to around 300,000 particles ≥ 1 
µm/ml and 1,400 particles ≥ 10 µm/ml after 6 months storage at 40°C going along with collapse and 
independent of whether the vials showed discolouration. Visual inspection showed that the 
reconstituted products exhibited flocculated visible particles. Collapse and partial decolouration led to 




Figure 6-3: Number of subvisible particles (A) ≥ 1 µm/ml of sucrose and arginine formulations with high and low 
RM over 6 months at 40°C and (B) ≥ 10 µm and 25 µm after 60 months at 40°C. 
 
All arginine based formulations showed comparable or lower particle levels after lyophilisation to the 
sucrose benchmark. Both ArgCitr and ArgPhos formulations resulted in an increase in particle count 
over 6 months up to approx. 140,000 particles ≥ 1 µm/ml and 80,000 particles ≥ 1 µm/ml with low and 
high RM, respectively. ArgCitr low RM exhibited around 2,000 particles ≥ 10 µm/ml and a few visible 
particles. SEC of ArgCitr and ArgPhos revealed an increase from 2% HMWS after lyophilisation to 
5 – 7% HMWS after 6 months at 40°C. In ArgLacto low RM the particle count increased up to 
100,000 particles ≥ 1 µm/ml and the HMWS to 2.5% after 6 months. ArgLacto high RM tended towards 
low particle counts with approx. 50,000 particles ≥ 1 µm/ml after storage and constant HWMS levels 




of 2.5%. Interestingly, both RM levels of ArgSucc were comparable with Suc low RM. Particle counts 
and HWMS formation did not exceed Suc low RM values. Therefore, ArgSucc showed a clear benefit 
to Suc resulting in a similar protein stability but neither collapse nor RM dependent protein stability. 
Interestingly, both ArgHCl formulations were clearly superior to Suc resulting in approx. 
10,000 particles ≥ 1 µm/ml after storage independent of the collapse level. HMWS level did not 
increase over 6 months storage. 
LMWS were between 0.3 – 0.7% for all samples, independent of storage except for collapsed and 
discoloured Suc high RM lyophilisates which exhibited up to 3% LMWS which led to an overall increase 
with high standard deviation. The discolouration and mAb instability of the collapsed Suc high RM 
lyophilisates was evaluated further. Boronate affinity chromatography (BAC) identified approx. 28% 
glycated mAb in these samples whereas glycated species were absent in any other formulation. 
 
 
Figure 6-4: HMWS (A) and LMWS (B) results for sucrose and arginine formulations with high and low RM over 6 
months at 40°C. 
 
The integrity of the mAb’s tertiary structure was exemplarily evaluated for ArgCitr, ArgHCl, and 
ArgPhos formulations of both RM levels after 6 months storage at 40°C with near-UV CD (Figure 6-5). 






Figure 6-5: Near-UV CD spectra for (A) ArgCitr, (B) ArgHCl, and (C) ArgPhos formulations before lyophilisation and 
after storage for 6 months at 40°C. 
 
Thus, overall mAb aggregation was more pronounced in ArgPhos, ArgCitr and to a lesser extend 
increased in ArgLacto compared to Suc. The Suc high RM exhibited collapse and discolouration after 
6 months and after 3 months already an increase in HMWS was observed. ArgSucc was comparable to 
sucrose. ArgHCl resulted in lower subvisible particles levels compared to sucrose even though the 
lyophilisates collapsed. RM did not influence protein stability in Arg formulations with a trend to better 
stability at higher RM values. Suc lyophilisates resulted in less protein stability with increased RM upon 
storage at 40°C. Comparing the individual counter ions, trivalent acids such as citric acid and 
phosphoric acid exhibited the worst protein stability. No clear conclusion could be drawn for mono- 
and bivalent acids. While ArgSucc was comparable to Suc, ArgHCl resulted in better protein stability 
but with a high risk of cake collapse. 
 
3.2 Glycation challenge study at higher temperature 
To further study the observed protein glycation and moisture dependent protein stability we 
additionally compared sucrose (Sucglyc), mannitol and sucrose mixture (Man:Suc 4:1), ArgCitrglyc, and 
ArgHClglyc with low and high RM upon storage at 25°C, 40°C, and 60°C over 9 months, assessing protein 
stability with light obscuration, SEC, and BAC. 
Sucglyc, Man:Suc, and ArgCitrglyc resulted in pharmaceutically elegant cakes for both RM levels, whereas 
ArgHClglyc exhibited a loss in cake structure. Low and high RM lyophilisates showed 0.1 - 0.5% RM and 
1.2 – 2.3% RM, respectively (Table 6-2). The Sucglyc formulation exhibited a Tg of 74°C and 50°C for low 
and high RM, respectively. The Man:Suc mixture resulted in the δ-Mannitol modification and a Tg of 
sucrose of 77°C for both RM levels. The Tg of ArgHClglyc was comparable to the Sucglyc lyophilisates, 
whereas ArgCitr had significantly higher Tg values.  




Table 6-2: Tg and RM of formulations for glycation challenge study. 
 Tg [°C] RM [%] 
 low RM high RM low RM high RM 
Sucglyc 73.6 ± 1.1 49.6 ± 2.1 0.3 ± 0.1 1.8 ± 0.2 
Man:Suc 4:1 77.0 ± 2.6 76.0 ± 1.8 0.3 ± 0.1 1.2 ± 0.1 
ArgCitrglyc 122.8 ± 0.9 97.7 ± 1.8 0.1 ± 0.1 1.6 ± 0.1 
ArgHClglyc 76.7 ± 7.7 48.8 ± 2.9 0.5 ± 0.3 2.3 ± 0.2 
 
 
Man:Suc and ArgCitrglyc cakes did not show a change in their appearance upon storage. Sucglyc high and 
low RM lyophilisates were collapsed after 9 months stored at 40°C and 60°C and both showed 
discolouration when stored at 60°C. ArgHClglyc cakes completely collapsed when stored at 40°C and 
60°C and ArgHClglyc high RM collapsed also at 25°C storage temperature. All products reconstituted 
within 1 minute except for collapsed Sucglyc low and high RM and ArgHClglyc high RM stored at 60°C over 
9 months which required more than 10 minutes for complete dissolution and the collapsed 
discoloured Sucglyc high RM samples stored at 60°C did not dissolve completely. 
A storage temperature of 60°C fostered discolouration in sucrose samples in an extreme manner. Due 
to its high Tg values, ArgCitrglyc can act as amorphous matrix at high storage temperatures, comparable 
to mannitol lyophilisates. ArgHClglyc high RM showed already at 25°C storage temperature collapse as 
well as the overall difficulties in freeze drying ArgHCl by cause of its low Tg’ values. 
With respect to protein stability, subvisible particle formation was not observed for any samples upon 
storage at 25°C (Figure 6-6). The particle counts remained below 36,000 particles ≥ 1 µm/ml. Sucglyc 
high RM resulted in increased particle counts over 1 month at 60°C already showing visible flocculated 
particles. After 9 months, less subvisible particles were found since large visible particles had formed. 
Furthermore, discoloured 60°C Sucglyc lyophilisates did not dissolve and were not analysed. ArgCitrglyc 
low RM showed a slight increase in subvisible particles at 25°C over 9 months. Storage at 40°C over 
9 months resulted in increased particle counts for ArgCitrglyc low RM, but not for high RM. This 
behaviour was also observed in the first study (see above) and more pronounced at 60°C storage. 
Man:Suc resulted in a drastic increase in particles over 9 months at 60°C only for low RM. Interestingly, 
collapsed ArgHClglyc preserved a low level of particles with less than 10,000 particles ≥ 1 µm/ml over 
9 months at 40°C. Only in low RM ArgHClglyc particle count increased to 72,000 particles ≥ 1 µm/ml over 






Figure 6-6: Number of particles (A) ≥ 1 µm/ml of glycation challenge study over 9 months at 25°C, 40°C, and 60°C 
and (B) ≥ 10 µm and ≥ 25 µm of glycation challenge study after 9 months at 25°C, 40°C, and 60°C. 
 
While Sucglyc, Man:Suc, and ArgHClglyc did not reveal a RM dependence in particle formation over 
storage, ArgCitrglyc showed lower particle counts in formulations with higher RM. Sucglyc and Man:Suc 
resulted in increased particle formation, especially upon storage at 60°C. While Sucglyc high RM 
collapsed upon storage at 40°C, Man:Suc was superior due to the crystalline matrix. Nevertheless, 
storage at 40°C did not increase particle formation. 
The starting level of 2% HMWS in Sucglyc remained constant over 9 months storage at 25°C and 40°C 
(Figure 6-7). Sucglyc low RM revealed only a slight increase in HWMS over 9 months at 60°C, whereas 
Sucglyc high RM showed a drastic increase, partially due to the reduced total AUC of the 
chromatographs related to the formation of larger insoluble particles. Furthermore, glycated species 
exhibit a higher absorbance spectra leading to higher HMWS values [26]. Within one month at 60°C, 
both low and high RM Sucglyc samples resulted in more than 25% glycated species (Table 6-3). This level 
was after 9 months increased up to 60% in low RM samples. Although more glycated species should 
form in high RM samples, the high amount of insoluble particles and the poor reconstitution resulted 
in many covalent bound aggregates. These aggregates were not recorded by BAC leading to an 
overrepresenting of the non-glycated species. Compared to Sucglyc, Man:Suc started with 2.2% HMWS, 
showing an increase to after 9 months at  40°C and 60°C up to 5% and 40%, respectively. The HMWS 
level after 9 months at 60°C was overestimated due to a higher absorbance spectra of the glycated 
species [26]. Man:Suc formulations exhibited glycated species already after 1 month storage. Only in 
Man:Suc high RM glycation was detectable after 9 months storage at 40°C, whereas no glycation was 
detectable in the corresponding Sucglyc formulations. ArgCitrglyc already started with a higher HMWS 
level after lyophilisation compared to Sucglyc and resulted in increased soluble aggregates at all storage 
temperatures. A slight tend towards lower HMWS formation was found for the high RM samples. After 
9 months, ArgCitrglyc exhibited around 5%, 8%, and 13% stored at 25°C, 40°C, and 60°C, respectively. 




Among the different formulations, ArgHClglyc was clearly superior due to the constant HWMS levels 
over storage. The HMWS level of 1.8% of ArgHClglyc did not increase over 9 months storage at 25°C, 
40°C, and 60°C. Compared to sucrose based cakes, no glycation was observed for the arginine based 
formulations. 
Overall, LMWS were low at 0.3 to 0.6 % in all samples, except for Man:Suc and ArgCitrglyc stored at 60°C 
which showed an increase to approx. 1% as well as Sucglyc high RM after 60°C storage but for latter the  
total AUC was reduced whereas the AUC of LMWS was unchanged. Interestingly ArgHClglyc did not 
exhibit an increase in LMWS over storage. 
 
 
Figure 6-7: HMWS (A) and LMWS (B) results for glycation challenge study over 9 months at 25°C, 40°C, and 60°C. 
 
Table 6-3: Glycated species. (n.d. = not detectable) 
 RM 
Glycated species 
t0 1 month 9 months 
 25°C 40°C 60°C 25°C 40°C 60°C 
Sucglyc 
low 
n.d. n.d. n.d. 
40.6 ± 5.9 % 
n.d. 
n.d. 
61.0 ± 17.5 % 
high 26.7 ± 9.2 % 41.5 ± 6.1 % 
Man:Suc 
4:1 
low 23.8 ± 0.5 % 41.5 ± 7.0 % 
high 22.3 ± 0.4 % 4.1 ± 0.6 % 58.5 ± 1.0 % 
ArgCitrglyc 
low 










Overall, collapsed Sucglyc and Man:Suc showed increased HMWS levels as well as glycation at 60°C with 
some effects noticeable also at 40°C and reduced protein stability with higher RM levels. Mannitol was 
able to form a crystalline matrix to inhibit cake macro-collapse but did not prevent glycation. ArgCitrglyc 
resulted in increased HMWS levels over storage with a slight RM dependence towards less protein 
instabilities at high RM. Again, ArgHClglyc despite collapse showed consistently low HMWS levels over 
9 months and now glycation. 
 
4. Conclusion 
The aim of this study was to investigate the influence of different residual moisture levels on protein 
stability of a model mAb in arginine based lyophilisates in comparison to sucrose based lyophilisates. 
Too low as well as too high RM levels can potentially destabilise the protein in amorphous sugar 
matrices [7-9]. Arginine lyophilisates with citrate, hydrochloride, lactobionate, phosphate, and 
succinate as counter ions were compared to a sucrose formulation, all freeze dried to RM levels of less 
than 0.5% and 2.5%. 
At low RM levels of 0.5%, Tg values of arginine based formulations were equal or higher than that of 
the sucrose based reference formulation. The increased RM level resulted in about 20°C lower Tg 
values. At high RM, Suc and ArgHCl showed the lowest Tg of all tested formulations at around 50°C, 
which may cause instabilities during accelerated storage conditions at 40°C but not at 2°C – 8°C. 
Proteins are stated to be well immobilised with a Tg at least 10°C – 20°C above the intended storage 
temperature [14, 27, 28]. According to the low Tg values, Suc and ArgHCl high RM resulted in macro-
collapse upon storage at 40°C and 60°C and ArgHCl high RM resulted in macro-collapse upon storage 
even at 25°C. 
Interestingly, ArgCitr, ArgLacto, and ArgPhos lyophilisates with high RM levels showed a trend to better 
protein stability over storage compared to their low RM equivalents. ArgHCl and ArgSucc low and high 
RM exhibited superior protein stability compared to Suc low RM over 6 months at 40°C. Suc high RM 
collapsed and discoloured after 6 months at 40°C and showed higher particle and HWMS levels 
compared to high RM arginine products. 
Additionally, glycation was detected in collapsed discoloured Sucglyc lyophilisates but not seen for 
arginine based formulations. Also, non macro-collapsed cakes achieved by adding mannitol to sucrose 
still revealed glycation. Glycation was not detected in arginine based lyophilisates. Formation of 
soluble mAb aggregates was observed in ArgCitrglyc formulations, more pronounced with higher RM. 




ArgHClglyc did not show no protein instability, independent of RM, although they collapsed at higher 
storage temperature. 
This study presents ArgHCl and ArgSucc as potential alternatives to improve the physical stability of 
mAb formulations to sucrose based formulations. Additionally, glycation was eliminated using arginine 
based formulations. ArgHCl lyophilisates were superior to Suc regarding the protein stability of the 
investigated mAb, but need to be combined with excipients to overcome cake collapse while 
maintaining protein stability.  
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Arginine hydrochloride (ArgHCl) can be used as stabiliser of protein drugs in both liquid and freeze 
dried formulations reducing aggregation. But ArgHCl exhibits a low Tg’ value which can lead to cake 
collapse during lyophilisation. We analysed arginine (Arg) citrate, hydrochloride and lactobionate 
based lyophilisates aiming for elegant cake appearance in combination with minimal protein 
aggregation using 2 mg/ml monoclonal antibody (mAb) without additional excipients and in 
combination with sucrose (Suc) as amorphous stabiliser as well as mannitol (Man) and phenylalanine 
(Phe) as crystalline bulking agents. Furthermore, 50 mg/ml mAb was also used. Based on a process 
which resulted in poor cake appearance for the ArgHCl based cake with 2 mg/ml mAb, the combination 
with sucrose, mannitol (Man:Arg 4:1) and phenylalanine (Phe:Arg 1:4, 1.5:3.5, and 2:3) as well as a 
high mAb concentration were able to improve cake appearance. Overall, the crystalline bulking agent 
Phe in combination with ArgHCl renders elegant cakes with minimal protein aggregation. The 
alternative Arg salts did not require cake quality enhancement, but mAb stability was inferior to 
ArgHCl. The combination with mannitol showed reduced stability due to a substantially lower amount 
of amorphous matrix. Thus, the combination of ArgHCl with phenylalanine was superior to any other 
formulation tested including the sucrose based and may allow for substantial process time reduction 
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Freeze drying of biopharmaceuticals is frequently used to achieve adequate storage stability [1]. The 
protein molecules are stabilized due to a reduced mobility in a glassy amorphous excipient matrix and 
by formation of hydrogen bonds with excipient molecules which thus replace the water molecules 
surrounding and stabilizing the protein molecules in solution [2, 3]. The most used stabilizing excipient 
with this respect is sucrose (Suc). Trehalose is another preferred non-reducing disaccharide for this 
purpose. In order to obtain pharmaceutically elegance of the cakes which is important for market and 
patient acceptance, freeze drying below the glass transition temperature of the maximally freeze 
concentrated solution Tg’ or at least below the collapse temperature Tc is usually required [4-6]. A 
collapsed amorphous matrix itself is not necessarily detrimental for protein stability [7-9]. But keeping 
the product temperature Tp below Tg’ or Tc during primary drying leads to extended process times 
coming along with higher costs [4, 10]. 
Besides sugars, amino acids are able to form amorphous matrices. They are already used in 
commercially available products and in a few cases completely sugar-free amino acid based 
formulations are used [11-15]. Especially L-arginine is of highest interest due to its ability to reduce 
protein-protein interactions and aggregation in liquid formulations and reconstituted lyophilisates [16, 
17]. This effect is driven by an interaction of arginine with the protein surface via hydrogen bond 
formation and ion-dipole interactions [18-20]. Furthermore, arginine (Arg) is able to form amorphous 
matrices in combination with different counter ions and can strongly reduce protein aggregation [21-
23]. The stabilising effect and the glass properties depend on the counter ion and whereas typically 
the best stability is achieved with the hydrochloride formulations, higher Tg’ and Tg values of the 
lyophilisates result with citrate, phosphate, or succinate salts [22, 23]. Arginine hydrochloride (ArgHCl) 
based cakes are prone to collapse during primary drying due to very low Tg’ of around -42.5°C 
compared to Suc with -32°C [23-26]. In comparison, the Tg’ of arginine citrate at pH 6.0 of approx. -28°C 
makes a suitable lyophilisation process easy [21]. 
There are different approaches to achieve a higher Tg’ or Tc to achieve fast primary drying without 
product collapse. This positive effect comes along with the use of high protein drug concentrations [4, 
5]. The Tg’ onset temperature of a 1:4 Suc to ArgHCl mixture went up from -40°C in placebo  to -32.5°C 
at 50 mg/ml mAb [23]. Furthermore, a low Tg’ value can be increased via mixtures with other excipients 
that form amorphous systems with a higher Tg’. A combined Tg’ value based on the Gordon-Taylor 
equation results [27]. In case of ArgHCl the Tg’ of a mAb formulation can be increased from -42.7°C to 
-34°C by using a Suc to ArgHCl 4:1 mix [22, 23, 28]. The mostly used approach to achieve an elegant 
cake and potentially run primary drying at a product temperature above the critical temperature of 




the amorphous matrix is the addition of a crystalline bulking agent [2, 12, 29]. Since the crystallising 
excipient has no protein stabilising abilities, its concentrations should be kept low to allow for enough 
amorphous cryo- and lyoprotectant considering the concentration limitation due to the isotonicity 
requirement of parenterals [30-32]. The most prominent bulking agent mannitol (Man) requires a high 
ratio of mannitol to sugar, typically 4:1 to ensure crystallising matrix formation [33]. Incomplete Man 
crystallisation can lead to lowered Tg of the lyophilisates and crystallisation events upon storage which 
reduces protein stability. The combination of Man with ArgHCl at ratios of 2:1 and 4:1 resulted in 
elegant cakes, making Man a promising candidate for ArgHCl formulations for lyophilisation [34], but 
protein stability was not assessed. Phenylalanine (Phe) was recently found to serve as crystallising 
bulking agent at lower concentrations leaving more room for the amorphous stabilising matrix. 
Avoiding Man by Phe resulted in lyophilisates with elegant appearance and good physical stability of a 
mAb at 5:45 and 10:40 Phe:Suc ratios [13]. 
Within this study, the main focus was on the improvement of the cake quality of an ArgHCl formulation 
for lyophilisation of biopharmaceuticals. To achieve this goal, i) the counter ion was varied from 
hydrochloride to citrate and lactobionate, ii) formulations with a high mAb concentration were 
evaluated and iii) mixtures with Suc, Man, and Phe were tested. We analysed mAb aggregation during 
the process as well as in the different formulations upon 6 months storage at 40°C. 
 
2. Materials and Methods 
2.1 Materials 
Stock solutions of L-arginine base (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), citric acid 
anhydrous (VWR International, Ismaning, Germany), lactobionic acid (Acros Organics, Geel, Belgium), 
sucrose (Merck KGaA, Darmstadt, Germany), and D-(-)-mannitol (Merck) were prepared with highly 
purified water (HPW). Furthermore, 1 M hydrochloric acid (VWR International) and L-phenylalanine 
(Merck) were used. 
A monoclonal IgG1 antibody (94 mg/ml, MW ca. 148 kDa, ϵ = 1.37 mL/mg∙cm, referred to as mAb) in 
15 mM histidine buffer pH 5.3 was used as model protein. Formulations contained 2 mg/ml mAb, 
formulations marked with HC contained 50 mg/ml mAb. For HC formulations, the mAb was dialysed 
against HPW with a 10-fold buffer exchange in Vivaspin® 20 Ultrafiltration Uni (30 kDa, Sartorius, 
Goettingen, Germany) and concentration checked after dialysis and formulation preparation at 





The pH of the arginine base stock solution (8% w/w) was titrated to pH 6.0 with hydrochloric acid 
(ArgHCl), citric acid (ArgCitr), or lactobionic acid (ArgLacto). The weight was recorded for further 
sample dilution with mAb and HPW until the final concentrations were reached. Suc, Man, or Phe were 
subsequently added as solid if required. Table 7-1 represents the formulation compositions. A solid 
content of around 5% was chosen to gain isotonic compositions.  Thereby, 2% arginine and 3.5% 
sucrose turned out to be isotonic, whereas less mannitol and phenylalanine were necessary and 
therefore used on 5% solid content basis. 
The formulations were filtered with 0.2 µm polyethersulfone membrane syringe filters (VWR 
International) prior to filling. 
 
Table 7-1: Excipient solid content ratios of formulations tested. *Content of counter ion (hydrochloric acid, citric 
acid, and lactobionic acid) required for pH adjustment not involved in ratio description. 
Acronym Arg base [% w/w]* Suc [% w/w] Man [% w/w] Phe [% w/w] 
-- / HC 5.0 -- -- -- 

















































Lyophilisation stoppers (B2-TR coating, West Pharmaceuticals Services Deutschland GmbH & Co. KG, 
Eschweiler, Germany) and DIN 2R Vials (Fiolax®, Schott AG, Mainz, Germany) were cleaned with HPW 
prior to use and dried at 60°C for 8 h. The vials were filled with 1.5 mL formulation and semi-stoppered 
subsequently. An FTS LyostarTM 3 freeze dryer (SP Scientific, Stone Ridge, NY, USA) was used with the 
protocols provided in Table 7-2. The product temperature was recorded with thermocouples and the 




end of primary drying was followed by comparative pressure measurement between Pirani and 
capacitance gauge. The vials were stoppered at 800 mbar after secondary drying and crimped with 
flip-off seals. Samples were analysed after lyophilisation and after 1, 3, and 6 months storage at 40°C. 
 
Table 7-2: Freeze drying protocols. * End of primary drying detected by comparative pressure measurement. 
Step Ramp [°C/min] TShelf [°C] Pressure [µbar] Hold time [h] 
Freezing 1 -50 - 1.5 
Primary Drying 0.5 -20 60 47 – 65* 
Secondary Drying 0.4 40 60 8.3 
 
2.2.2 Cake appearance 
Images of the lyophilised products were taken in front of a black background with a Nikon D5300 
camera (Nikon GmbH, Düsseldorf, Germany) to visualise cake appearance. 
 
2.2.3 Differential scanning calorimetry (DSC) 
The glass transition temperature of the maximally freeze concentrated solution (Tg’) was determined 
with a DSC 821e (Mettler Toledo, Gießen, Germany). 25 µl liquid sample were filled into 40 µl 
aluminium crucibles and hermetically sealed. The samples were cooled to -60°C at 10°C/min and 
heated to 25°C at 10°C/min. The midpoint of the phase transition was determined as Tg’. To analyse 
the glass transition (Tg) of the lyophilised products approx. 10 mg crushed cake were filled at ≤ 10% 
r.h. conditions into 40 µl aluminium crucibles and hermetically sealed. The samples were heated to 
80°C at 10°C/min, cooled to 10°C at 10°C/min, and reheated to 120°C. The midpoint of the phase 
transition in the second heating was determined as Tg. 
 
2.2.4 Karl-Fischer titration 
Coulometric Karl-Fischer titration with a headspace module (AQUA 40.00, Analytik Jena AG, Halle, 
Germany) was used for residual moisture (RM) analysis. About 20 mg crushed lyophilised powder were 
transferred into a fresh 2R vial at ≤ 10% r.h. and heated up to 100°C in the headspace module. The 





2.2.5 X-Ray powder diffraction (XRPD) 
An X-Ray Diffractometer XRD 3000 TT (Rich. Seifert & Co. GmbH & Co. KG, Ahrensberg, Germany) 
equipped with a Cu Kα (40 kV, 30 mA, λ = 154.17 pm) was used to analyse powder morphology from 
5 – 45° 2θ with steps of 0.05° 2θ and 2 seconds per step. 
 
2.2.6 Reconstitution time 
Samples were reconstituted with HPW, vials gently rolled by hand and the time until complete 
dissolution based on visual inspection was considered as reconstitution time. 
 
2.2.7 Light obscuration 
A PAMAS SVSS-C35 particle counter with an HCB-LD-25/25 sensor (Partikelmess- und Analysensysteme 
GmbH, Ruthesheim, Germany) was used for characterising subvisible particles between 1 µm and 
200 µm by light obscuration. After sample pre-rinse with 0.2 mL, each sample was analysed 4 times 
with 0.2 mL according to USP 787 [35]. Between each sample, the system was rinsed with 0.2 µm 
filtered HPW. At least 3 samples per formulation were used for the subvisible particle count calculation 
of particles ≥ 1 µm per mL. 
 
2.2.8 High performance size exclusion chromatography (HP-SEC) 
An Agilent 1100 series HPLC system equipped with an UV/Vis detector (280 nm; Agilent Technologies, 
Santa Clara, CA, USA) was used for analysing higher and lower molecular weight species 
(HMWS/LMWS) by size exclusion chromatography. A Waters AQUITY UPLC Protein BEH 200Å column 
was used with 50 mM sodium phosphate pH 6.0 with 400 mM sodium perchlorate at 0.4 mL/min. All 
samples were centrifuged at 7000 rpm for 10 min prior to use (Force7, Denver Instruments, Bohemia, 
NY, USA). The integrated peak area was determined after blank subtraction and relative areas 
calculated with the ChemStation software (Agilent Technologies). 
 
 




3. Results and Discussion 
3.1 Screening of arginine salts with different excipients 
Aim of this study was to achieve good cake appearance and protein stability using arginine based 
lyophilisates. For this purpose, the counter ion was varied and the standard hydrochloride replaced by 
citrate and lactobionate. These salts were combined with either a higher mAb concentration of 
50 mg/ml compared to 2 mg/ml standard, Suc as amorphous cryo- and lyoprotectant, and Man and 
Phe as crystalline bulking agents. 
Arginine salts vary substantially in Tg’ depending on pH and valency [28]. Whereas the hydrochloride 
form rendered a Tg’ value of -46.3°C at pH 6.0, the citrate and the lactobionate forms showed markedly 
higher values of -27.1°C and -25.6°C indicating a higher probability of good cake appearance. With a 
higher mAb concentration Tg’ was increased, corresponding to literature [4, 31, 36], to -23.1°C, -21.4°C, 
and -32.5°C for ArgCitr, ArgLacto, and ArgHCl respectively. A Suc:Arg 3.5:2 mixture exhibited decreased 
Tg’ values of -30.4°C for ArgCitr and -28.8°C for ArgLacto and an increased value of -38.2°C for ArgHCl 
according to the Gordon-Taylor equation stating a mixed Tg’ based on the individual mass fraction and 
Tg’ values (Suc Tg’ = -32°C [26]) [37]. Mixtures with the crystallising bulking agents Phe:Arg 1:4 and 
Man:Arg 4:1 did show the Tg’ values of the Arg salts.  
 
3.1.1 Characteristics of the arginine based products  
Both pure ArgCitr and ArgLacto resulted in pharmaceutically elegant lyophilisates, whereas ArgHCl 
products showed pronounced collapse and major structural defects. At 50 mg/ml mAb 
pharmaceutically elegant cakes could be obtained in all cases which reflects the rise in Tg’ and collapse 
temperature with higher protein concentration. The mixture of ArgHCl with sucrose (Suc:Arg 3.5:2) 
resulted in elegant macroscopic appearance with some shrinkage and detachment from the vial wall 
due to the increase in Tg’. The combination of sucrose with the other Arg salts did not lead to change 
of appearance. Both Phe:Arg 1:4 and Man:Arg 4:1 cakes were pharmaceutically elegant for all arginine 
salts due to the crystalline scaffold. Man:Arg ratios of less than 4:1 were not sufficient to form 
pharmaceutically elegant products (Figure 7-1). The macroscopic appearance of all lyophilisates did 






Figure 7-1: Macroscopic appearance of arginine lyophilisates mixed with mannitol at ratios of Man:Arg 4.5:0.5, 
4:1, 3:2, 2:3, and 1:4 after lyophilisation. 
 
All lyophilisates resulted in less than 1.2% RM. The Tg of ArgHCl cakes of 74°C, independent of the 
protein concentration, decreased with addition of Suc and Phe to 55°C and 69°C, respectively. A similar 
trend was found for ArgCitr and ArgLacto based products. They exhibited a Tg of 120°C and 100°C, 
respectively, decreasing with Suc and Phe. The lowest Tg was 80°C with the addition of Suc to both 
formulations. Still this Tg was more than 20°C above storage temperature and therefore not considered 
critical for collapse upon storage [38].  
Man containing formulations resulted in δ-mannitol after freeze drying (Figure 7-2). Peaks of 
crystalline Phe could not be detected although appearance and DSC indicated Phe crystallisation. The 
high content of amorphous matrix appears to cover the crystalline structures and shields the signal of 
Phe in the XRPD [12]. The morphology of the formulations did not change upon storage, except for 
ArgHCl which partially crystallised upon storage for 3 months at 40°C. Crystallisation of ArgHCl was 
inhibited by the high mAb concentration and in the mixture with sucrose or phenylalanine. 




Reconstitution of all samples was completed within 10 seconds which extended to 3 min for ArgCitr 
HC and ArgLacto HC upon storage. 
 
 
Figure 7-2: XRPD of (A) ArgHCl, (B) ArgCitr, and (C) ArgLacto lyophilisates with 2 mg/ml mAb without excipient 
and as Suc:Arg 3.5:2, Phe:Arg 1:4, and Man:Arg 4:1 mixtures and with 50 mg/ml mAb (HC) at t0. In (A), 
crystallisation of ArgHCl 2 mg/ml mAb lyophilisates is depicted after 3 months at 40°C (t3). 
 
3.1.2 mAb process and storage stability  
The effect of the Arg salts pure and in combination with the other excipients was studied considering 
the colloidal stability based on formation of subvisible particles (Figure 7-3) and soluble aggregates 
(Figure 7-4A). Pure ArgHCl as benchmark resulted in approx. 10,000 particles ≥ 1 µm/ml and remained 
at this t0-level after 6 months storage at 40°C. An increase in protein concentration did not affect 
particle levels but resulted in marked formation of HMWS upon storage. The addition of Suc to ArgHCl 
did not change mAb stability. The Man:Arg 4:1 mixture showed substantial aggregate formation after 
6 months storage at 40°C with around 6% soluble aggregates, 140,000 particles ≥ 1 µm/ml, up to 
1000 particles ≥ 10 µm and a few visible particles. Varying the Man:Arg ratios did not improve protein 
stability (Figure 7-5 and 7-6). The addition of Phe to ArgHCl formulations at a 1:4 ratio did not 
compromise protein stability compared to ArgHCl without additional excipients. 
Both alternative arginine salts ArgCitr and ArgLacto provided less mAb stabilisation during both the 
process and upon storage compared to ArgHCl. Sucrose had a positive effect on these formulations 
decreasing particle and HMWS formation. Nevertheless, the Suc mixtures with ArgCitr or ArgLacto 
were inferior to the ArgHCl-Suc mixture and this was still slightly inferior to the pure ArgHCl and the 
ArgHCl Arg:Phe 4:1 mixture. 
In all formulations, LMWS levels remained between 0.2 – 0.8% upon storage and only mixtures with 





Thus, the Arg salt alternatives ArgCitr and ArgLacto resulted in better cake appearance than ArgHCl 
but were inferior with respect to process and storage stability. Furthermore, high mAb concentrations 
provided pharmaceutically elegant lyophilisates in all Arg salts but exhibited less protein stability 
especially pronounced HMWS formation. Mixtures with Man did not provide process and storage 
stability. The addition of Suc and Phe improved the cake appearance of ArgHCl lyophilisates and the 
mixture with Phe provided outstanding process and storage stability. Due to the high amount of the 




Figure 7-3: (A) Number of subvisible particles ≥ 1 µm/ml of arginine based 2 mg/ml mAb lyophilisates without 
further excipient (-), as mix with Suc, Man, Phe or 50 mg/ml mAb (HC) after lyophilisation (t0) and upon storage 
for 1 (t1), 3 (t3), and 6 months (t6) at 40°C. (B) Number of subvisible particles ≥ 10 µm/ml and ≥ 25 µm/ml after 
6 months at 40°C. 
 
 
Figure 7-4: (A) Higher molecular weight species (HMWS) and (B) lower molecular weight species (LMWS) of 
arginine based lyophilisates with 2 mg/ml mAb (-), as a mix with Suc, Man, and Phe, and with 50 mg/ml mAb (HC) 
after lyophilisation (t0) and upon storage for 1 (t1), 3 (t3) and 6 months (t6). 
 





Figure 7-5: Subvisible particle count in arginine based 2 mg/ml mAb lyophilisates in Man:Arg ratios of 4.5:0.5, 
4:1, 3:2, 2:3, and 1:4 after lyophilisation (t0) and upon storage for 3 (t3) and 6 (t6) months. 
 
 
Figure 7-6: (A) Higher molecular weight species (HMWS) and (B) lower molecular weight species (LMWS) of 
arginine based 2 mg/ml mAb lyophilisates in Man:Arg ratios of 4.5:0.5, 4:1, 3:2, 2:3, and 1:4 after lyophilisation 
(t0) and upon storage for 3 (t3) and 6 (t6) months. 
 
3.2 Effect of Phe:Arg ratio on mAb lyophilisates 
In a next step, the Phe:Arg ratio was varied to study the impact of a level of crystalline bulking agent 
which may result in more elegant cakes at the expense of protein stability. ArgCitr and ArgLacto 
lyophilisates showed an adequate appearance compared to ArgHCl lyophilisates. But their stabilization 
potential is lower, potentially enhancing the effect of a decrease in amount of amorphous matrix 






3.2.1 Powder characteristics of Arg based lyophilisates with different Phe:Arg ratios 
A Phe:Arg ratio of 0.5:4.5 was not sufficient to avoid the collapse of ArgHCl based cakes whereas all 
other mixtures rendered lyophilisates of pharmaceutical elegance that did not change upon storage 
(Figure 7-7). At Phe:Arg 1:4 slight shrinkage and detachment of the cake from the vial wall was 
noticeable. All ArgHCl based lyophilisates with Phe showed a Tg of 60°C to 70°C and 0.6 – 1% RM which 
changed slightly to 60°C and 1.3 – 1.6%, respectively, upon 6 months storage at 40°C (Figure 7-8). A 
higher increase in RM with almost no decrease in Tg for vacuum- and freeze-dried sugar-free arginine 
formulations was also observed previously compared to sucrose containing formulations [13], but the 
mechanistics behind are unclear. 
Both ArgCitr and ArgLacto did not require the Phe addition to achieve pharmaceutically elegant cakes 
in the first place. Accordingly, pharmaceutically elegant cakes were obtained in all mixtures with Phe 
and the appearance did not change upon storage. Both exhibited high Tg values above 80°C at 
0.4 – 1.0% RM after lyophilisation. Upon storage, the Tg values decreased by 10°C at most 
accompanied by a slight increase in RM. Overall, the formulations tend towards higher RM levels and 
lower Tg values with higher Phe fraction.  
Crystallisation of phenylalanine could not be proven by XRPD in any of the lyophilisates, but 
crystallisation of ArgHCl was observed in Phe:Arg 0.5:4.5 products after 3 months storage at 40°C. All 
samples reconstituted within 10 seconds but after 6 months at 40°C reconstitution of lyophilisates 
with the highest Phe fraction, Phe:Arg 2:3, took 1, 3 and 6 min, respectively, for ArgCitr, ArgLacto, and 
ArgHCl. 
 





Figure 7-7: Macroscopic appearance of arginine based lyophilisates with 2 mg/ml mAb mixed with Phe:Arg ratios 
of 0.5:4.5, 1:4, 1.5:3.5, and 2:3 after lyophilisation. 
 
 
Figure 7-8: (A) Tg and (B) RM of arginine based lyophilisates with 2 mg/ml mAb mixed with Phe:Arg ratios of 





3.2.2 mAb process and storage stability in different Phe:Arg ratio lyophilisates 
The mAb stability in the lyophilisates was evaluated based on subvisible particle analysis by light 
obscuration (Figure 7-9) and SEC (Figure 7-10A). The ArgHCl based formulations resulted in less 
than 10,000 particles ≥ 1 µm/ml after lyophilisation, independent of the Phe concentration, and 
remained at this t0-level upon storage for 6 months at 40°C in case of an Phe:Arg ratio of 0.5:4.5 or 1:4. 
Higher Phe:Arg ratios exhibited a slight increase in subvisible particles up to 40,000 particles ≥ 1 µm/ml 
upon storage. Formation of HMWS was not observed upon storage. 
Both process and storage stability were reduced in ArgCitr containing Phe. A substantial increase in 
particles ≥ 1 µm and ≥ 10 µm was observed. This was accompanied by a trend towards higher particle 
levels with increasing Phe:Arg ratio potentially due to a reduction of the amount of amorphous Arg 
matrix. The 0.5:4.5 and 1.5:3.5 Phe:Arg formulations tended towards HMWS formation upon storage. 
Process stability of ArgLacto with Phe was reduced as particle formation was already observed for all 
Phe concentrations after lyophilisation. The formulations did not show mAb aggregation upon storage 
for 6 months at 40°C based on HMWS and subvisible particle levels, with an overall trend towards less 
particles ≥ 10 µm with higher Phe concentrations. 
Fragmentation of the mAb was not observed during lyophilisation or upon storage (Figure 7-10B). 
Thus, ArgHCl formulations with Phe:Arg ratios of 1:4, 1.5:3.5, and 2:3 form elegant cakes with 
outstanding protein stability. The higher ratio of Phe:Arg 2:3 showed a slightly decreased protein 
stability with minor increase in particle formation and slower reconstitution. This ratio provides 
sufficient ArgHCl stabiliser, but the high amount of crystallising Phe appears to have a negative impact 
on process stability. Phe:Arg 0.5:4.5 was not sufficient to form elegant lyophilisates and ArgHCl 
partially crystallised. The alternative Arg salts were not able to stabilise the protein in a similar manner 
as ArgHCl. ArgCitr exhibited a substantial increase in particle formation with an increase in Phe content. 
ArgLacto resulted in elegant products already without the need for a bulking agent, which makes 
handling convenient. The addition of Phe did not change protein stability except for a decrease in 
≥ 10 µm particle levels with higher Phe concentrations. Both HCl and Lacto are monovalent counter 
ions to Arg with Lacto as sugar acid potentially showing different interactions with Arg. Therefore, 
monovalent acids might be beneficial for the protein stabilising effects of the Arg salts. Citr as 
tricarboxylic acid showed different glass forming abilities with Arg, which were not suitable for 
sufficient protein stability [21]. The interaction of Phe in combination with Arg salts is so far not 
understood. Regardless of the valency of the counter ion, Phe containing lyophilisates showed 
improved protein storage stability compared to the Arg salts without further excipient. The 
hydrophobic nature of Phe exposed to the protein surface in the reconstituted state could potentially 








Figure 7-9: (A) Subvisible particle count in arginine based 2 mg/ml mAb lyophilisates mixed with Phe:Arg ratios 
of 0.5:4.5, 1:$, 1.5:3.5, and 2:3 after lyophilisation (t0) and upon storage for 6 months (t6). (B) Number of 
subvisible particles ≥ 10 µm/ml and ≥ 25 µm/ml after 6 months at 40°C. 
 
 
Figure 7-10: (A) Higher molecular weight species (HMWS) and (B) lower molecular weight species (LMWS) of 
arginine based 2 mg/ml mAb lyophilisates mixed with Phe:Arg ratios of 0.5:4.5, 1:4, 1.5:3.5, and 2:3 after 









The aim of this study was to find formulations based on Arg, which render both pharmaceutically 
elegant cakes and outstanding protein stability. Arg formulations can overcome potential drawbacks 
of sucrose-based formulations for lyophilisation, such as cleavage of sucrose eventually causing 
glycation of the mAb. Pure ArgHCl lyophilisates exhibit very good protein stability but at least partially 
collapse during freeze-drying because of the low Tg’. We used 2 mg/ml mAb as standard in our study 
and investigated the effect of i) a higher mAb concentration of 50 mg/ml, ii) the addition of sucrose as 
amorphous stabiliser with a higher Tg’, iii) mannitol and phenylalanine as crystalline bulking agents, 
and iv) citrate and lactobionate as arginine counter ion alternatives to hydrochloride. 
A high mAb concentration of 50 mg/ml mAb rendered pharmaceutically elegant cakes due a significant 
increase of Tg’, to -32.5°C, but protein stability was compromised upon storage for 6 months at 40°C 
as indicated by the formation of HMWS. The addition of sucrose to ArgHCl also increased Tg’, but only 
to -38°C, which is still critical with respect to the lyophilisation process. The combination of ArgHCl 
with sucrose improved cake appearance and protein stability compared to a pure sucrose formulation 
[22]. With respect to the crystalline bulking agents, a high amount of Man was required to improve 
cake appearance, which reduced the amount of ArgHCl as stabiliser and therefore caused mAb 
perturbations. Phenylalanine on the other hand was able to form pharmaceutically elegant cakes even 
at low concentrations (Phe:Arg 1:4, 1.5:3.5, and 2:3). Furthermore, protein stability during both 
lyophilisation and upon storage was comparable or even superior to a pure ArgHCl formulation. Using 
a ratio of Phe:Arg 1:4 or Phe 1.5:3.5 provided the best results regarding cake appearance and protein 
stability. At these concentrations, reconstitution times were not affected by the hydrophobic amino 
acid Phe [12]. 
The alternative Arg salts ArgCitr and ArgLacto already showed Tg’ values high enough to avoid collapse 
in a conventional lyophilisation cycle yielding elegant cake appearance without the addition of 
crystallising bulking agents. However, ArgCitr lyophilisates showed markedly reduced protein stability 
with pronounced particle formation compared to ArgHCl. ArgLacto formulations were better than 
ArgCitr but inferior to ArgHCl. Thus, depending on the sensitivity of the protein, ArgLacto may be a 
suitable candidate next to ArgHCl for the sugar-free formulation of biopharmaceuticals. 
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The present thesis focused mainly on two aspects in lyophilization of biopharmaceuticals which have 
not been explored yet in detail: i) determining the water content of the maximally freeze concentrated 
solution (FC) (Chapter 3) with understanding of the protein stability in the FC (Chapter 4) and ii) the 
use of arginine (Arg) in combinations with different counter ions as amorphous matrix for lyophilisation 
of a monoclonal antibody (mAb) (Chapter 5), the effect of residual moisture on Arg based lyophilisates 
and mAb stability (Chapter 6), and elegant cake appearance with high protein stability based on Arg 
hydrochloride (Chapter 7). 
In order to understand protein stability in the FC it is at first important to know its exact composition, 
i.e. the water content. A linear regression method taking solid content and change in the enthalpy 
measured by DSC into account was developed (Chapter 3). Various systems containing sugar (sucrose, 
trehalose) and other excipients (histidine buffer, phosphate buffer, NaCl, Arg hydrochloride, Arg 
citrate) with different mAb concentrations exhibited a solid content of 70 – 80% and 20 – 30% 
unfrozen water. The type of excipient had slight influence but not the mAb concentration. In the next 
step, a method to generate the extremely viscous FCs was developed based on partial freeze-drying 
and adjustment of the water content (Chapter 4). By this, we prepared different FCs containing mAb, 
sucrose, histidine or phosphate buffer, and NaCl. An increase in sugar or buffer concentration resulted 
in a positive influence on both mAb melting and aggregation temperature as well as on mAb self-
interaction. Storage of the FCs above Tg’ for up to 1 month did not affect protein integrity. Thus, 
exceeding Tg’ during freeze drying, e.g. upon annealing or during primary drying, is not expected to 
negatively impact mAb stability. This important finding result also applies, beyond just freeze-drying, 
to storage of frozen bulk material. 
Sucrose based formulations are the gold-standard in freeze-drying of biologics. They may however still 
require further improvement when it comes to protein stability and could potentially lead to glycation 
after sucrose cleavage. Arg is known to stabilise proteins due to its ability to bind to the protein surface 
as well as charge shielding effects. We formulated a mAb in Arg with the citrate, hydrochloride, 
lactobionate, phosphate, and succinate as counter-ion (Chapter 5) and studied the performance upon 
freeze-drying as well as the physicochemical characteristics and the mAb stability of the lyophilisates. 
Arg hydrochloride collapsed and partially crystallised upon storage but provided best protein stability. 
The citrate, lactobionate, and phosphate salts formed elegant cakes but had deficits in protein stability. 





the other hand improve mAb stability for the other counter-ions. At higher mAb concentration, only 
the hydrochloride and the lactobionate provided sufficient protein stability next to sucrose. 
The same arginine salts were analysed regarding their ability to stabilise a mAb at different residual 
moisture levels (Chapter 6). Lyophilisates with two different residual moisture levels of less than 0.5% 
and of approx. 2.5% were stored for up to 6 months at 40°C. The mAb aggregation in Arg hydrochloride 
and succinate was similar or even less compared to a sucrose reference formulation, while Arg citrate, 
lactobionate and phosphate resulted in lower protein stability. Despite decreased Tg values, which is 
still above 50°C, Arg formulations with high RM levels exhibited better protein stability. Glycation of 
the mAb was detected in sucrose based formulations, but did not occur in Arg based formulations. 
Since Arg hydrochloride resulted in very good protein stability but poor cake appearance with partial 
collapse, as presented in Chapters 5 and 6, ways to improve the cake appearance were investigated 
(Chapter 7). Arg hydrochloride and, for comparison, citrate and lactobionate were studied alone and 
in combination with i) a higher mAb concentration, ii) sucrose as an amorphous matrix former with 
higher Tg’ and iii) in combination with mannitol and phenylalanine as crystalline bulking agents. At least 
a 4:1 ratio of mannitol to Arg or a 1:4 ratio of phenylalanine to Arg were required to improve cake 
appearance. Only phenylalanine containing formulations exhibited a very good protein stabilising 
effect similar to pure ArgHCl. Addition of mannitol led to markedly reduced amount of the stabilising 
amorphous matrix former Arg hydrochloride, considering the solute limitations given by isotonicity, 
and in consequence to drastically reduced mAb stability. ArgCitr and ArgLacto did not require cake 
improvement but again, mAb stability is clearly inferior. Higher mAb concentrations also resulted in 
adequate cake appearance but came at the expense of reduced stability. Thus, we could demonstrate 
that Arg is a highly valuable amorphous matrix former for lyophilisation of proteins. Using the 
hydrochloride, a combination with phenylalanine is recommended in order to achieve adequate cake 
appearance. The crystalline bulking agent also allows for faster processing as it enables a higher 
product temperature during primary drying. A higher residual moisture is well tolerated by Arg based 
products which could be an important benefit over sucrose based lyophilisates. 
In summary, this thesis provided several new findings regarding the freeze drying of mAb. We 
established new tools for characterisation and preparing the freeze concentrate. Protein stability is 
not negatively affected in this concentrated state even when exceeding Tg’ for up to 1 month. We also 
demonstrated that Arg is a highly suitable stabiliser in protein lyophilisates, especially in combination 
with phenylalanine as crystalline bulking agent. 
 
